Cidofovir dihydrate (Synonyms: 西多福韦二水合物; GS 0504 dihydrate; HPMPC dihydrate; (S)-HPMPC dihydrate)

目录号: HY-17438A: Data Sheet 产品使用指南
FAQs
技术支持

Cidofovir (GS 0504; HPMPC; (S)-HPMPC) dihydrate 是一种无环单磷酸核苷酸类似物，CMV 抑制剂，具有抗病毒活性。Cidofovir dihydrate 可通过选择性抑制病毒 DNA 聚合酶 (DNA polymerase) 来抑制巨细胞病毒 (CMV) 复制。Cidofovir dihydrate 可诱导细胞凋亡 (apoptosis)，用于巨细胞病毒性视网膜炎、疱疹、癌症研究。Cidofovir dihydrate 还具有抗正痘病毒 (orthopoxvirus) 和抗天花病毒活性。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Cidofovir dihydrate Chemical Structure

CAS No. : 149394-66-1

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
5 mg	￥330	1 - 2 周
10 mg	￥450	1 - 2 周
50 mg	￥900	1 - 2 周
100 mg	￥1400	1 - 2 周
200 mg		询价
500 mg		询价

or 大包装询价

* Please select Quantity before adding items.

Other Forms of Cidofovir dihydrate:

Cidofovir In-stock
Cidofovir sodium 询价

MCE 顾客使用本产品发表的 10 篇科研文献

Cidofovir dihydrate 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性
纯度 & 产品资料
参考文献

生物活性

Cidofovir (GS 0504; HPMPC; (S)-HPMPC) dihydrate is an acyclic monophosphate nucleotide analogue and CMV inhibitor with antiviral activity. Cidofovir dihydrate inhibits cytomegalovirus (CMV) replication by selectively inhibiting viral DNA polymerase. Cidofovir dihydrate induces apoptosis and can be used in studies of AIDS cytomegalovirus retinitis, herpes, and cancer^[1]^[3]. Cidofovir dihydrate also has anti-orthopoxvirus and anti-variola activities^[4].

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
A549	CC₅₀	50.6 μM Compound: 2	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by alamarBlue assay Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by alamarBlue assay	[PMID: 31711794]
A549	EC₅₀	16.5 μM Compound: HPMPC, GS-504	Antiviral activity against Human adenovirus type 11p slobitski infected in A549 cells assessed as inhibition of DNA replication by QPCR assay Antiviral activity against Human adenovirus type 11p slobitski infected in A549 cells assessed as inhibition of DNA replication by QPCR assay	[PMID: 20585112]
A549	EC₅₀	19.9 μM Compound: HPMPC, GS-504	Antiviral activity against Human adenovirus type 5 F2853-5b infected in A549 cells assessed as inhibition of DNA replication by QPCR assay Antiviral activity against Human adenovirus type 5 F2853-5b infected in A549 cells assessed as inhibition of DNA replication by QPCR assay	[PMID: 20585112]
A549	EC₅₀	20 μM Compound: Cidofovir	Antiviral activity against Adenovirus type 5 F2853-5b infected in human A549 cells assessed as inhibition of viral replication after 24 hrs by RT-PCR analysis Antiviral activity against Adenovirus type 5 F2853-5b infected in human A549 cells assessed as inhibition of viral replication after 24 hrs by RT-PCR analysis	[PMID: 22369233]
BSC-1	CC₅₀	423.5 μM Compound: HPMPC	Cytotoxicity against african green monkey BSC1 cells Cytotoxicity against african green monkey BSC1 cells	[PMID: 17420214]
BSC-1	CC₅₀	> 100 μM Compound: cidofovir	Cytotoxicity against african green monkey BSC1 cells assessed as ATP levels after 4 days by CellTitre-Glo Luminescent Cell Viability assay Cytotoxicity against african green monkey BSC1 cells assessed as ATP levels after 4 days by CellTitre-Glo Luminescent Cell Viability assay	[PMID: 23320521]
BSC-1	EC₅₀	132 μM Compound: cidofovir, CDV	Antiviral activity against Vaccinia virus WR in BSC1 cells assessed as protection from virus-induced lysis of cell monolayer after 20 hrs Antiviral activity against Vaccinia virus WR in BSC1 cells assessed as protection from virus-induced lysis of cell monolayer after 20 hrs	[PMID: 18808105]
BSC-1	EC₅₀	17.8 μM Compound: HPMPC	Antiviral activity against Simian virus 40 PML2 DAR in african green monkey BSC1 cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Simian virus 40 PML2 DAR in african green monkey BSC1 cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17420214]
BSC-1	EC₅₀	19 μM Compound: HPMPC	Antiviral activity against Simian virus 40 A2895 in african green monkey BSC1 cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Simian virus 40 A2895 in african green monkey BSC1 cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17420214]
BSC-1	EC₅₀	19.3 μM Compound: HPMPC	Antiviral activity against Simian virus 40 PML1 EK in african green monkey BSC1 cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Simian virus 40 PML1 EK in african green monkey BSC1 cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17420214]
BSC-1	EC₅₀	50 μM Compound: cidofovir, CDV	Antiviral activity against Vaccinia virus WR in BSC1 cells assessed as reduction in plaque formation after 20 hrs Antiviral activity against Vaccinia virus WR in BSC1 cells assessed as reduction in plaque formation after 20 hrs	[PMID: 18808105]
BSC-1	IC₅₀	11.5 μM Compound: cidofovir	Antiviral activity against Vaccinia virus WR infected in african green monkey BSC1 cells after 4 days by plaque reduction assay Antiviral activity against Vaccinia virus WR infected in african green monkey BSC1 cells after 4 days by plaque reduction assay	[PMID: 23320521]
Bone marrow cell	CC₅₀	6 μM Compound: cidofovir	Cytotoxicity against human bone marrow cells assessed as inhibition of CFU-GM formation after 15 days Cytotoxicity against human bone marrow cells assessed as inhibition of CFU-GM formation after 15 days	[PMID: 17329103]
C-33-A	CC₅₀	> 300 μM Compound: Cidofovir	Cytotoxicity in human C-33-A cells by CellTiter-Glo reagent assay Cytotoxicity in human C-33-A cells by CellTiter-Glo reagent assay	[PMID: 27933957]
C3H	EC₅₀	> 4 μg/mL Compound: HPMPC, cidofovir	Antiviral activity against MSV in C3H cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against MSV in C3H cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17948980]
CCRF-CEM	CC₅₀	> 200 μM Compound: Cidofovir	Compound concentration required to reduce viability of CEM cells Compound concentration required to reduce viability of CEM cells	[PMID: 14643328]
CCRF-CEM	EC₅₀	> 10 μM Compound: Cidofovir	Antiviral activity against HIV1 IIIB in CEM cells Antiviral activity against HIV1 IIIB in CEM cells	[PMID: 16392791]
CCRF-CEM	EC₅₀	> 10 μM Compound: Cidofovir	Antiviral activity against HIV2 ROD in CEM cells Antiviral activity against HIV2 ROD in CEM cells	[PMID: 16392791]
CCRF-CEM	EC₅₀	> 200 μM Compound: Cidofovir	Compound was tested for anti-viral activity against HIV-1 in CEM cells Compound was tested for anti-viral activity against HIV-1 in CEM cells	[PMID: 14643328]
CCRF-CEM	EC₅₀	> 200 μM Compound: Cidofovir	Compound was tested for anti-viral activity against HIV-2 in CEM cells Compound was tested for anti-viral activity against HIV-2 in CEM cells	[PMID: 14643328]
CCRF-CEM	EC₅₀	> 20 μg/mL Compound: HPMPC, cidofovir	Antiviral activity against HIV1 3B in CEM cells assessed as reduction of virus-induced cytopathogenicity after 4 days Antiviral activity against HIV1 3B in CEM cells assessed as reduction of virus-induced cytopathogenicity after 4 days	[PMID: 17948980]
CCRF-CEM	EC₅₀	> 20 μg/mL Compound: HPMPC, cidofovir	Antiviral activity against HIV2 ROD in CEM cells assessed as reduction of virus-induced cytopathogenicity after 4 days Antiviral activity against HIV2 ROD in CEM cells assessed as reduction of virus-induced cytopathogenicity after 4 days	[PMID: 17948980]
CHO	CC₅₀	255 μM Compound: Cidofovir	Cytotoxicity against CHO cells expressing hOAT1 after 120 hrs by Cell-Titer Glo assay Cytotoxicity against CHO cells expressing hOAT1 after 120 hrs by Cell-Titer Glo assay	[PMID: 19001108]
CHO	CC₅₀	520 μM Compound: Cidofovir	Cytotoxicity against CHO cells after 120 hrs by Cell-Titer Glo assay Cytotoxicity against CHO cells after 120 hrs by Cell-Titer Glo assay	[PMID: 19001108]
CHO	CC₅₀	>= 2000 μM Compound: Cidofovir	Ratio of CC50 for CHO cells to CC50 for CHO cells expressing hOAT1 after 120 hrs by Cell-Titer Glo assay Ratio of CC50 for CHO cells to CC50 for CHO cells expressing hOAT1 after 120 hrs by Cell-Titer Glo assay	[PMID: 19001108]
CHO	IC₅₀	60 μM Compound: Cidofovir	TP_TRANSPORTER: inhibition of 6-Carboxyfluorescein uptake in OAT1-expressing CHO cells TP_TRANSPORTER: inhibition of 6-Carboxyfluorescein uptake in OAT1-expressing CHO cells	[PMID: 10929807]
COS-7	CC₅₀	49 μM Compound: Cidofovir	Cytotoxicity against JC polyomavirus MAD-4 infected grivet COS7 cells assessed as reduction in cell viability after 7 days by cell titer-glo assay Cytotoxicity against JC polyomavirus MAD-4 infected grivet COS7 cells assessed as reduction in cell viability after 7 days by cell titer-glo assay	[PMID: 27624078]
COS-7	EC₅₀	2 μM Compound: Cidofovir	Antiviral activity against JC polyomavirus MAD-4 infected in grivet COS7 cells assessed as reduction in DNA copy number after 7 days by PCR analysis Antiviral activity against JC polyomavirus MAD-4 infected in grivet COS7 cells assessed as reduction in DNA copy number after 7 days by PCR analysis	[PMID: 27624078]
Ca-Ski	EC₅₀	> 100000 nM Compound: Cidofovir	Antiproliferative activity against HPV-transformed human CaSki cells after 7 days by SRB assay Antiproliferative activity against HPV-transformed human CaSki cells after 7 days by SRB assay	[PMID: 19398642]
HEK293	CC₅₀	> 300 μM Compound: Cidofovir	Cytotoxicity in HEK293 cells by XTT assay Cytotoxicity in HEK293 cells by XTT assay	[PMID: 27933957]
HEL	CC₅₀	121 μM Compound: cidofovir	Cytotoxicity against HEL cells Cytotoxicity against HEL cells	[PMID: 17518459]
HEL	CC₅₀	133 μM Compound: cidofovir	Cytotoxicity against human HEL cells assessed as reduction of cell growth Cytotoxicity against human HEL cells assessed as reduction of cell growth	[PMID: 17672445]
HEL	CC₅₀	150.02 μM Compound: Cidofovir	Cytotoxicity against human HEL cells assessed as reduce in cell growth incubated for 3 days by coulter counter analysis Cytotoxicity against human HEL cells assessed as reduce in cell growth incubated for 3 days by coulter counter analysis	[PMID: 33479570]
HEL	CC₅₀	153 μM Compound: Cidofovir	Cytotoxicity against human HEL cells assessed as cell growth reduction incubated for 3 days Cytotoxicity against human HEL cells assessed as cell growth reduction incubated for 3 days	[PMID: 26291038]
HEL	CC₅₀	158 μM Compound: Cidofovir	Cytostatic concentration required to inhibit HEL cell proliferation measured at day 4 Cytostatic concentration required to inhibit HEL cell proliferation measured at day 4	[PMID: 15027877]
HEL	CC₅₀	161 μM Compound: Cidofovir	Cytotoxicity against HEL Cytotoxicity against HEL	[PMID: 23743443]
HEL	CC₅₀	175 μM Compound: Cidofovir	Cytotoxicity against HEL cells assessed as reduction of cell growth Cytotoxicity against HEL cells assessed as reduction of cell growth	[PMID: 20064723]
HEL	CC₅₀	21.3 μg/mL Compound: HPMC (Cidofovir)	Cytotoxic concentration to reduce the 50% cell growth of human embryonic lung cells Cytotoxic concentration to reduce the 50% cell growth of human embryonic lung cells	[PMID: 15658861]
HEL	CC₅₀	21.3 μg/mL Compound: HPMC (Cidofovir)	Cytotoxic concentration to reduce the 50% cell growth of human embryonic lung cells Cytotoxic concentration to reduce the 50% cell growth of human embryonic lung cells	[PMID: 15658861]
HEL	CC₅₀	216 μM Compound: Cidofovir	Cytotoxicity against HEL cells assessed as reduction in cell growth after 3 days by coulter counter method Cytotoxicity against HEL cells assessed as reduction in cell growth after 3 days by coulter counter method	[PMID: 28757102]
HEL	CC₅₀	234 μM Compound: 2, (S)-HPMPC	Cytotoxicity against human HEL cells assessed as growth inhibition after 3 days by coulter counter Cytotoxicity against human HEL cells assessed as growth inhibition after 3 days by coulter counter	[PMID: 21565516]
HEL	CC₅₀	23 μg/mL Compound: cidofovir	Cytotoxicity against HEL cells Cytotoxicity against HEL cells	[PMID: 16480257]
HEL	CC₅₀	241 μM Compound: Cidofovir	Cytotoxicity against HEL cells assessed as effect on cell growth incubated for 3 days by Coulter counter assay Cytotoxicity against HEL cells assessed as effect on cell growth incubated for 3 days by Coulter counter assay	[PMID: 22858222]
HEL	CC₅₀	254 μM Compound: Cidofovir	Cytotoxicity against human HEL cells after 3 days by coulter counter Cytotoxicity against human HEL cells after 3 days by coulter counter	[PMID: 21745746]
HEL	CC₅₀	280 μM Compound: (S)-CDV, HPMPC	Cytotoxicity against human HEL cells after 3 days Cytotoxicity against human HEL cells after 3 days	[PMID: 21128666]
HEL	CC₅₀	317 μM Compound: cidofovir	Inhibition of cell growth in HEL cells. Inhibition of cell growth in HEL cells.	[PMID: 10966745]
HEL	CC₅₀	35.4 μg/mL Compound: Cidofovir	Cytotoxicity against HEL Cytotoxicity against HEL	10.1007/s00044-011-9776-0
HEL	CC₅₀	400 μg/mL Compound: Cidofovir	Cytotoxicity against Cytomegalovirus infected HEL cells assessed as change in cell morphology Cytotoxicity against Cytomegalovirus infected HEL cells assessed as change in cell morphology	[PMID: 19324473]
HEL	CC₅₀	47 μg/mL Compound: cidofovir	Cytotoxicity against HEL cells assessed as reduction of cell growth after 3 days Cytotoxicity against HEL cells assessed as reduction of cell growth after 3 days	[PMID: 17869124]
HEL	CC₅₀	47 μg/mL Compound: cidofovir	Cytotoxicity against HEL cells assessed as reduction of growth after 3 days Cytotoxicity against HEL cells assessed as reduction of growth after 3 days	[PMID: 18835175]
HEL	CC₅₀	51 μM Compound: cidofovir	Cytotoxicity against HEL cells assessed as cell growth after 7 days Cytotoxicity against HEL cells assessed as cell growth after 7 days	[PMID: 17539622]
HEL	CC₅₀	51 μM Compound: cidofovir	Cytotoxicity against HEL cells assessed as reduction in cell growth Cytotoxicity against HEL cells assessed as reduction in cell growth	[PMID: 17961851]
HEL	CC₅₀	511 μM Compound: (S)-HPMPC	Cytotoxicity against HEL Cytotoxicity against HEL	[PMID: 20809641]
HEL	CC₅₀	54 μM Compound: Cidofovir	Cytotoxicity against human HEL cells assessed as reduction in cell growth after 3 days Cytotoxicity against human HEL cells assessed as reduction in cell growth after 3 days	[PMID: 19339082]
HEL	CC₅₀	57 μg/mL Compound: Cidofovir	Cytotoxicity against Cytomegalovirus infected HEL cells assessed as reduction in cell growth Cytotoxicity against Cytomegalovirus infected HEL cells assessed as reduction in cell growth	[PMID: 19324473]
HEL	CC₅₀	64 μM Compound: Cidofovir	Cytostatic against human HEL cells assessed as reduction in cell growth after 3 days by coulter counter Cytostatic against human HEL cells assessed as reduction in cell growth after 3 days by coulter counter	[PMID: 22578783]
HEL	CC₅₀	74 μM Compound: HPMPC, Cidofovir	Cytotoxicity against human HEL cells assessed as reduction of growth after 3 days Cytotoxicity against human HEL cells assessed as reduction of growth after 3 days	[PMID: 19226140]
HEL	CC₅₀	76 μg/mL Compound: HPMPC, cidofovir	Cytotoxicity against HEL cells assessed as cell growth after 3 days Cytotoxicity against HEL cells assessed as cell growth after 3 days	[PMID: 17948980]
HEL	CC₅₀	> 150 μM Compound: (S)-HPMPC (cidofovir)	Cytotoxic concentration required to reduce HEL cell growth by 50% Cytotoxic concentration required to reduce HEL cell growth by 50%	[PMID: 15081019]
HEL	CC₅₀	> 150 μM Compound: Cidofovir	Cytotoxic concentration required to reduce HEL cell growth Cytotoxic concentration required to reduce HEL cell growth	[PMID: 15801851]
HEL	CC₅₀	> 200 μg/mL Compound: (S)-HPMPC	Cytotoxic concentration required to reduce cell growth HEL cells (after 3 days) by 50 % Cytotoxic concentration required to reduce cell growth HEL cells (after 3 days) by 50 %	10.1016/0960-894X(95)00278-2
HEL	CC₅₀	> 250 μM Compound: Cidofovir	Cytotoxicity against HEL cells after 3 days by coulter counter analysis Cytotoxicity against HEL cells after 3 days by coulter counter analysis	[PMID: 21232828]
HEL	CC₅₀	> 300 μM Compound: Cidofovir	Cytotoxicity against HEL cells infected with Cytomegalovirus assessed as growth inhibition Cytotoxicity against HEL cells infected with Cytomegalovirus assessed as growth inhibition	[PMID: 27750154]
HEL	CC₅₀	> 300 μM Compound: Cidofovir	Cytostatic activity against HEL cells after 3 days by Coulter counting method Cytostatic activity against HEL cells after 3 days by Coulter counting method	[PMID: 29407990]
HEL	CC₅₀	> 300 μM Compound: Cidofovir	Cytotoxicity against human HEL cells assessed as reduction in cell viability measured after 3 days by beckman coulter counting method Cytotoxicity against human HEL cells assessed as reduction in cell viability measured after 3 days by beckman coulter counting method	[PMID: 33894564]
HEL	CC₅₀	> 317 μM Compound: HPMPC	Cytotoxicity against human HEL cells assessed as reduction in cell proliferation incubated for 3 days by Coulter counter method Cytotoxicity against human HEL cells assessed as reduction in cell proliferation incubated for 3 days by Coulter counter method	[PMID: 32676147]
HEL	CC₅₀	> 350 μM Compound: Cidofovir	Compound concentration required to reduce viability of HEL cells Compound concentration required to reduce viability of HEL cells	[PMID: 14643328]
HEL	CC₅₀	> 350 μM Compound: Cidofovir	Cytotoxicity against human HEL cells after 3 days by Coulter counting method Cytotoxicity against human HEL cells after 3 days by Coulter counting method	[PMID: 23911854]
HEL	CC₅₀	> 358 μM Compound: Cidofovir	Cytotoxic activity against HEL cells assessed as reduction in cell proliferation after 3 days by coulter counting method Cytotoxic activity against HEL cells assessed as reduction in cell proliferation after 3 days by coulter counting method	[PMID: 28682067]
HEL	CC₅₀	> 358 μM Compound: Cidofovir	Cytotoxicity against HEL cells assessed as reduction in cell viability after 3 days by coulter counting method Cytotoxicity against HEL cells assessed as reduction in cell viability after 3 days by coulter counting method	[PMID: 29268134]
HEL	CC₅₀	> 358 μM Compound: Cidofovir	Cytostatic activity against HEL cells after 3 days by Coulter counting method Cytostatic activity against HEL cells after 3 days by Coulter counting method	[PMID: 29550734]
HEL	CC₅₀	> 358 μM Compound: Cidofovir	Cytotoxicity against HEL cells assessed as reduction in cell viability after 3 days by coulter counting method Cytotoxicity against HEL cells assessed as reduction in cell viability after 3 days by coulter counting method	[PMID: 29670705]
HEL	CC₅₀	> 50 μg/mL Compound: Cidofovir	Cytotoxic concentration reducing HEL cell growth by 50%. Cytotoxic concentration reducing HEL cell growth by 50%.	[PMID: 12217359]
HEL	CC₅₀	>= 18 μg/mL Compound: Cidofovir	Cytotoxicity against human HEL cells assessed as reduction of cell growth Cytotoxicity against human HEL cells assessed as reduction of cell growth	[PMID: 17583388]
HEL	CC₅₀	>= 208 μM Compound: CDV	Cytotoxicity against human cytomegalovirus infected HEL cells assessed as cell growth inhibition incubated for 3 days by coulter counter method Cytotoxicity against human cytomegalovirus infected HEL cells assessed as cell growth inhibition incubated for 3 days by coulter counter method	[PMID: 26443550]
HEL	EC₅₀	0.0095 μg/mL Compound: Cidofovir	Antiviral activity against Varicella Zoster Virus OKA infected in HEL cells assessed as reduction in virus plaque formation Antiviral activity against Varicella Zoster Virus OKA infected in HEL cells assessed as reduction in virus plaque formation	[PMID: 19324473]
HEL	EC₅₀	0.03 μg/mL Compound: HPMPC, cidofovir	Antiviral activity against VZV 07-1 TK- in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against VZV 07-1 TK- in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17948980]
HEL	EC₅₀	0.044 μM Compound: (S)-CDV, HPMPC	Antiviral activity against VZV OKA expressing thymidine kinase infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 5 days Antiviral activity against VZV OKA expressing thymidine kinase infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 5 days	[PMID: 21128666]
HEL	EC₅₀	0.045 μM Compound: HPMPC, Cidofovir	Antiviral activity against foscarnet-resistant HCMV AD169 clone C infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against foscarnet-resistant HCMV AD169 clone C infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 19226140]
HEL	EC₅₀	0.069 μM Compound: HPMPC, Cidofovir	Antiviral activity against wild type HCMV Davis infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against wild type HCMV Davis infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 19226140]
HEL	EC₅₀	0.069 μg/mL Compound: (S)-HPMPC, cidofovir	Antiviral activity against acyclovir-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against acyclovir-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 18707089]
HEL	EC₅₀	0.07 μM Compound: (S)-CDV, HPMPC	Antiviral activity against thymidine kinase-deficient VZV 07/1 infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 5 days Antiviral activity against thymidine kinase-deficient VZV 07/1 infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 5 days	[PMID: 21128666]
HEL	EC₅₀	0.073 μg/mL Compound: (S)-HPMPC, cidofovir	Antiviral activity against TK- VZV 07-1 in HEL cells assessed as inhibition of plaque formation Antiviral activity against TK- VZV 07-1 in HEL cells assessed as inhibition of plaque formation	[PMID: 17298047]
HEL	EC₅₀	0.075 μg/mL Compound: Cidofovir	Antiviral activity against human cytomegalovirus AD169 infected HEL cells assessed as reduction in virus plaque formation Antiviral activity against human cytomegalovirus AD169 infected HEL cells assessed as reduction in virus plaque formation	[PMID: 17583388]
HEL	EC₅₀	0.076 μM Compound: HPMPC, Cidofovir	Antiviral activity against wild type HCMV AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against wild type HCMV AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 19226140]
HEL	EC₅₀	0.077 μg/mL Compound: (S)-HPMPC, cidofovir	Antiviral activity against VZV OKA in HEL cells assessed as inhibition of plaque formation Antiviral activity against VZV OKA in HEL cells assessed as inhibition of plaque formation	[PMID: 17298047]
HEL	EC₅₀	0.092 μM Compound: HPMPC, Cidofovir	Antiviral activity against PMEDAP-resistant HCMV AD169 clone 4 infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against PMEDAP-resistant HCMV AD169 clone 4 infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 19226140]
HEL	EC₅₀	0.095 μM Compound: HPMPC, Cidofovir	Antiviral activity against acyclovir-resistant HCMV AD169 clone 1 infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against acyclovir-resistant HCMV AD169 clone 1 infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 19226140]
HEL	EC₅₀	0.09 μg/mL Compound: (S)-HPMPC, cidofovir	Antiviral activity against HSV1 KOS in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against HSV1 KOS in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 17298047]
HEL	EC₅₀	0.09 μg/mL Compound: HPMPC, cidofovir	Antiviral activity against VZV OKA in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against VZV OKA in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17948980]
HEL	EC₅₀	0.1 μM Compound: 2, (S)-HPMPC	Antiviral activity against VZV 07/1 infected in HEL cells assessed as protection against virus-induced cytopathicity Antiviral activity against VZV 07/1 infected in HEL cells assessed as protection against virus-induced cytopathicity	[PMID: 21565516]
HEL	EC₅₀	0.102 μM Compound: Cidofovir	Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as inhibition of virus plaque formation after 4 days Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as inhibition of virus plaque formation after 4 days	[PMID: 22459876]
HEL	EC₅₀	0.12 μg/mL Compound: cidofovir	Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus plaque formation after 5 days Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus plaque formation after 5 days	[PMID: 17869124]
HEL	EC₅₀	0.12 μg/mL Compound: cidofovir	Antiviral activity against human cytomegalovirus Davis in HEL cells assessed as inhibition of viral cytopathicity Antiviral activity against human cytomegalovirus Davis in HEL cells assessed as inhibition of viral cytopathicity	[PMID: 18835175]
HEL	EC₅₀	0.15 μg/mL Compound: HPMPC, cidofovir	Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17948980]
HEL	EC₅₀	0.16 μM Compound: (S)-HPMPC (cidofovir)	Effective concentration against human cytomegalovirus AD-169 strain in HEL cell cultures Effective concentration against human cytomegalovirus AD-169 strain in HEL cell cultures	[PMID: 15081019]
HEL	EC₅₀	0.18 μg/mL Compound: Cidofovir	Effective concentration against AD-169 strain of CMV virus expressed in HEL cells Effective concentration against AD-169 strain of CMV virus expressed in HEL cells	[PMID: 15689173]
HEL	EC₅₀	0.18 μg/mL Compound: HPMPC, cidofovir	Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17948980]
HEL	EC₅₀	0.1 μg/mL Compound: (S)-HPMPC, cidofovir	Antiviral activity against foscarnet-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against foscarnet-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 18707089]
HEL	EC₅₀	0.1 μg/mL Compound: cidofovir	Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus plaque formation after 5 days Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus plaque formation after 5 days	[PMID: 17869124]
HEL	EC₅₀	0.1 μg/mL Compound: cidofovir	Antiviral activity against human cytomegalovirus AD169 in HEL cells assessed as inhibition of viral cytopathicity Antiviral activity against human cytomegalovirus AD169 in HEL cells assessed as inhibition of viral cytopathicity	[PMID: 18835175]
HEL	EC₅₀	0.24 μg/mL Compound: Cidofovir	Antiviral activity against Cytomegalovirus AD169 infected in HEL cells assessed as reduction in virus plaque formation Antiviral activity against Cytomegalovirus AD169 infected in HEL cells assessed as reduction in virus plaque formation	[PMID: 19324473]
HEL	EC₅₀	0.29 μM Compound: 2, (S)-HPMPC	Antiviral activity against VZV OKA infected in HEL cells assessed as protection against virus-induced cytopathicity Antiviral activity against VZV OKA infected in HEL cells assessed as protection against virus-induced cytopathicity	[PMID: 21565516]
HEL	EC₅₀	0.29 μg/mL Compound: Cidofovir	Effective concentration against Davis strain of CMV virus expressed in HEL cells Effective concentration against Davis strain of CMV virus expressed in HEL cells	[PMID: 15689173]
HEL	EC₅₀	0.2 μg/mL Compound: (S)-HPMPC, cidofovir	Antiviral activity against HCMV AD169 in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against HCMV AD169 in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 17298047]
HEL	EC₅₀	0.2 μg/mL Compound: Cidofovir	Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay	[PMID: 20971531]
HEL	EC₅₀	0.2 μg/mL Compound: HPMPC, cidofovir	Antiviral activity against HSV1 KOS in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against HSV1 KOS in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17948980]
HEL	EC₅₀	0.3 μM Compound: Cidofovir	Antiviral activity against HCMV AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against HCMV AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 21232828]
HEL	EC₅₀	0.3 μM Compound: HPMPC, Cidofovir	Antiviral activity against HCMV AD169 infected in human HEL cells assessed inhibition of virus-induced cytopathicity after 7 days postinfection Antiviral activity against HCMV AD169 infected in human HEL cells assessed inhibition of virus-induced cytopathicity after 7 days postinfection	[PMID: 19226140]
HEL	EC₅₀	0.35 μg/mL Compound: (S)-HPMPC, cidofovir	Antiviral activity against HSV2 G in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against HSV2 G in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 17298047]
HEL	EC₅₀	0.369 μM Compound: Cidofovir	Antiviral activity against Cytomegalovirus AD-169 infected in HEL cells assessed as inhibition of virus plaque formation after 4 days Antiviral activity against Cytomegalovirus AD-169 infected in HEL cells assessed as inhibition of virus plaque formation after 4 days	[PMID: 22459876]
HEL	EC₅₀	0.37 μg/mL Compound: Cidofovir	Antiviral activity against Cytomegalovirus Davis infected in HEL cells assessed as reduction in virus plaque formation Antiviral activity against Cytomegalovirus Davis infected in HEL cells assessed as reduction in virus plaque formation	[PMID: 19324473]
HEL	EC₅₀	0.38 μM Compound: Cidofovir	Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as inhibition of virus plaque formation Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as inhibition of virus plaque formation	[PMID: 27639368]
HEL	EC₅₀	0.38 μg/mL Compound: (S)-HPMPC, cidofovir	Antiviral activity against ACV-resistant TK- HSV1 KOS in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against ACV-resistant TK- HSV1 KOS in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 17298047]
HEL	EC₅₀	0.3 μg/mL Compound: (S)-HPMPC, cidofovir	Antiviral activity against HCMV Davis in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against HCMV Davis in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 17298047]
HEL	EC₅₀	0.3 μg/mL Compound: Cidofovir	Antiviral activity against Human herpesvirus 5 Davis infected human HEL cells assessed as reduction in the virus plaque formation Antiviral activity against Human herpesvirus 5 Davis infected human HEL cells assessed as reduction in the virus plaque formation	10.1007/s00044-011-9776-0
HEL	EC₅₀	0.4 μM Compound: Cidofovir	Antiviral activity against HCMV Davis infected in HEL cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against HCMV Davis infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 21232828]
HEL	EC₅₀	0.4 μM Compound: Cidofovir	Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus plaque formation Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus plaque formation	[PMID: 27639368]
HEL	EC₅₀	0.41 μM Compound: Cidofovir	Antiviral activity against human cytomegalovirus Davis infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 7 days post infection Antiviral activity against human cytomegalovirus Davis infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 7 days post infection	[PMID: 19339082]
HEL	EC₅₀	0.41 μM Compound: cidofovir	Antiviral activity against human cytomegalovirus AD169 in HEL cells assessed as reduction of plaque formation after 7 days Antiviral activity against human cytomegalovirus AD169 in HEL cells assessed as reduction of plaque formation after 7 days	[PMID: 17539622]
HEL	EC₅₀	0.41 μM Compound: cidofovir	Antiviral activity against human cytomegalovirus Davis in HEL cells assessed as reduction of plaque formation after 7days Antiviral activity against human cytomegalovirus Davis in HEL cells assessed as reduction of plaque formation after 7days	[PMID: 17539622]
HEL	EC₅₀	0.41 μM Compound: cidofovir	Antiviral activity against HCMV AD169 infected in HEL cells assessed as reduction of virus-induced cytopathogenicity after 3 days Antiviral activity against HCMV AD169 infected in HEL cells assessed as reduction of virus-induced cytopathogenicity after 3 days	[PMID: 17961851]
HEL	EC₅₀	0.41 μM Compound: cidofovir	Antiviral activity against HCMV Davis infected in HEL cells assessed as reduction of virus-induced cytopathogenicity after 3 days Antiviral activity against HCMV Davis infected in HEL cells assessed as reduction of virus-induced cytopathogenicity after 3 days	[PMID: 17961851]
HEL	EC₅₀	0.42 μg/mL Compound: HPMPC, cidofovir	Antiviral activity against HSV2 Lyons in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against HSV2 Lyons in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17948980]
HEL	EC₅₀	0.42 μg/mL Compound: HPMPC, cidofovir	Antiviral activity against acyclovir-resistant HSV1 KOS TK- in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against acyclovir-resistant HSV1 KOS TK- in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17948980]
HEL	EC₅₀	0.43 μg/mL Compound: (S)-HPMPC, cidofovir	Antiviral activity against HSV2 Lyons in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against HSV2 Lyons in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 17298047]
HEL	EC₅₀	0.49 μg/mL Compound: (S)-HPMPC, cidofovir	Antiviral activity against HCMV 6 with U97 mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against HCMV 6 with U97 mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 18707089]
HEL	EC₅₀	0.4 μg/mL Compound: Cidofovir	Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay	[PMID: 20971531]
HEL	EC₅₀	0.5 μM Compound: (S)-HPMPC (cidofovir)	Effective concentration against human cytomegalovirus Davies strain in HEL cell cultures Effective concentration against human cytomegalovirus Davies strain in HEL cell cultures	[PMID: 15081019]
HEL	EC₅₀	0.5 μM Compound: HPMPC, Cidofovir	Antiviral activity against HCMV Davis infected in human HEL cells assessed inhibition of virus-induced cytopathicity after 7 days postinfection Antiviral activity against HCMV Davis infected in human HEL cells assessed inhibition of virus-induced cytopathicity after 7 days postinfection	[PMID: 19226140]
HEL	EC₅₀	0.51 μM Compound: Cidofovir	Antiviral activity against Cytomegalovirus Davis infected in human HEL cells assessed as reduction in virus plaque formation Antiviral activity against Cytomegalovirus Davis infected in human HEL cells assessed as reduction in virus plaque formation	[PMID: 23911856]
HEL	EC₅₀	0.51 μM Compound: Cidofovir	Antiviral activity against Human cytomegalovirus Davis expressed in HEL cells assessed as reduction in plaque formation incubated for 7 days by Giemsa stain based microscopy Antiviral activity against Human cytomegalovirus Davis expressed in HEL cells assessed as reduction in plaque formation incubated for 7 days by Giemsa stain based microscopy	[PMID: 26291038]
HEL	EC₅₀	0.51 μM Compound: Cidofovir	Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as inhibition of virus plaque formation Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as inhibition of virus plaque formation	[PMID: 27639368]
HEL	EC₅₀	0.55 μM Compound: HPMPC, Cidofovir	Antiviral activity against HPMPA-resistant HCMV AD169 clone 2 mutant infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against HPMPA-resistant HCMV AD169 clone 2 mutant infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 19226140]
HEL	EC₅₀	0.57 μM Compound: Cidofovir	Compound was tested for anti-viral activity against HSV-1(KOS) in HEL cells Compound was tested for anti-viral activity against HSV-1(KOS) in HEL cells	[PMID: 14643328]
HEL	EC₅₀	0.57 μM Compound: Cidofovir	Antiviral activity against HSV1 KOS in HEL cells Antiviral activity against HSV1 KOS in HEL cells	[PMID: 16392791]
HEL	EC₅₀	0.59 μg/mL Compound: (S)-HPMPC, cidofovir	Antiviral activity against ganciclovir-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against ganciclovir-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 18707089]
HEL	EC₅₀	0.6 μM Compound: Cidofovir	Effective concentration required to inhibit HCMV AD169 strain-induced cytopathicity in human embryonic lung (HEL) fibroblast cell cultures at day 7 of postinfection Effective concentration required to inhibit HCMV AD169 strain-induced cytopathicity in human embryonic lung (HEL) fibroblast cell cultures at day 7 of postinfection	[PMID: 15027877]
HEL	EC₅₀	0.6 μM Compound: Cidofovir	Effective concentration required to inhibit human cytomegalo virus AD-169 induced cytopathicity in HEL fibroblast cell line after 7 days of postinfection Effective concentration required to inhibit human cytomegalo virus AD-169 induced cytopathicity in HEL fibroblast cell line after 7 days of postinfection	[PMID: 15801851]
HEL	EC₅₀	0.61 μM Compound: Cidofovir	Antiviral activity against Human cytomegalovirus AD169 expressed in HEL cells assessed as reduction in plaque formation incubated for 7 days by Giemsa stain based microscopy Antiviral activity against Human cytomegalovirus AD169 expressed in HEL cells assessed as reduction in plaque formation incubated for 7 days by Giemsa stain based microscopy	[PMID: 26291038]
HEL	EC₅₀	0.62 μg/mL Compound: (S)-HPMPC, cidofovir	Antiviral activity against HCMV 530 with U97 and DNA polymerase mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against HCMV 530 with U97 and DNA polymerase mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 18707089]
HEL	EC₅₀	0.64 μg/mL Compound: Cidofovir	Antiviral activity against human cytomegalovirus Davis infected HEL cells assessed as reduction in virus plaque formation Antiviral activity against human cytomegalovirus Davis infected HEL cells assessed as reduction in virus plaque formation	[PMID: 17583388]
HEL	EC₅₀	0.65 μg/mL Compound: HPMPC, cidofovir	Antiviral activity against HSV2 G in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against HSV2 G in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17948980]
HEL	EC₅₀	0.66 μM Compound: cidofovir	Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus plaque formation Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus plaque formation	[PMID: 17518459]
HEL	EC₅₀	0.66 μM Compound: cidofovir	Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus plaque formation Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus plaque formation	[PMID: 17518459]
HEL	EC₅₀	0.67 μM Compound: cidofovir	Antiviral activity against CMV AD169 in human HEL cells after 7 days Antiviral activity against CMV AD169 in human HEL cells after 7 days	[PMID: 17672445]
HEL	EC₅₀	0.67 μM Compound: cidofovir	Antiviral activity against CMV Davis in human HEL cells after 7 days Antiviral activity against CMV Davis in human HEL cells after 7 days	[PMID: 17672445]
HEL	EC₅₀	0.7 μM Compound: Cidofovir	Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus plaque formation Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus plaque formation	[PMID: 27639368]
HEL	EC₅₀	0.74 μM Compound: HPMPC, Cidofovir	Antiviral activity against ganciclovir-resistant HCMV AD169 clone 4 infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against ganciclovir-resistant HCMV AD169 clone 4 infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 19226140]
HEL	EC₅₀	0.79 μg/mL Compound: (S)-HPMPC, cidofovir	Antiviral activity against HCMV 521 with U97 and DNA polymerase mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against HCMV 521 with U97 and DNA polymerase mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 18707089]
HEL	EC₅₀	0.8 μM Compound: Cidofovir	Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 21232828]
HEL	EC₅₀	0.8 μM Compound: Cidofovir	Antiviral activity against thymidine kinase deficient acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against thymidine kinase deficient acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 21232828]
HEL	EC₅₀	0.83 μM Compound: CDV	Antiviral activity against human cytomegalovirus AD169 infected in HEL cells assessed as reduction in viral plaque formation Antiviral activity against human cytomegalovirus AD169 infected in HEL cells assessed as reduction in viral plaque formation	[PMID: 26443550]
HEL	EC₅₀	0.84 μM Compound: CDV	Antiviral activity against human cytomegalovirus Davis infected in HEL cells assessed as reduction in viral plaque formation Antiviral activity against human cytomegalovirus Davis infected in HEL cells assessed as reduction in viral plaque formation	[PMID: 26443550]
HEL	EC₅₀	0.86 μM Compound: Cidofovir	Antiviral activity against Cytomegalovirus AD-169 infected in human HEL cells assessed as reduction of plaque formation Antiviral activity against Cytomegalovirus AD-169 infected in human HEL cells assessed as reduction of plaque formation	[PMID: 23811093]
HEL	EC₅₀	0.8 μg/mL Compound: Cidofovir	Antiviral activity against Human herpesvirus 5 strain AD169 infected human HEL cells assessed as reduction in the virus plaque formation Antiviral activity against Human herpesvirus 5 strain AD169 infected human HEL cells assessed as reduction in the virus plaque formation	10.1007/s00044-011-9776-0
HEL	EC₅₀	0.9 μM Compound: Cidofovir	Antiviral activity against Cytomegalovirus Davis infected in HEL cells assessed as reduction of viral plaque formation Antiviral activity against Cytomegalovirus Davis infected in HEL cells assessed as reduction of viral plaque formation	[PMID: 20064723]
HEL	EC₅₀	0.9 μM Compound: Cidofovir	Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days	[PMID: 22459876]
HEL	EC₅₀	0.9 μM Compound: Cidofovir	Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days	[PMID: 22459876]
HEL	EC₅₀	0.9 μM Compound: Cidofovir	Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 23099097]
HEL	EC₅₀	0.9 μM Compound: Cidofovir	Antiviral activity against Human simplex virus 1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis Antiviral activity against Human simplex virus 1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis	[PMID: 23603046]
HEL	EC₅₀	0.9 μM Compound: Cidofovir	Antiviral activity against Human simplex virus 2 G infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis Antiviral activity against Human simplex virus 2 G infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis	[PMID: 23603046]
HEL	EC₅₀	0.9 μM Compound: Cidofovir	Antiviral activity against thymidine kinase-deficient Human simplex virus 1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis Antiviral activity against thymidine kinase-deficient Human simplex virus 1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis	[PMID: 23603046]
HEL	EC₅₀	0.92 μM Compound: 2, (S)-HPMPC	Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as protection against virus-induced cytopathicity Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as protection against virus-induced cytopathicity	[PMID: 21565516]
HEL	EC₅₀	0.92 μM Compound: Cidofovir	Antiviral activity against HCMV Davis infected in HEL cells by viral CPE assay Antiviral activity against HCMV Davis infected in HEL cells by viral CPE assay	[PMID: 22858222]
HEL	EC₅₀	0.92 μM Compound: Cidofovir	Antiviral activity against Cytomegalovirus AD-169 infected in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Cytomegalovirus AD-169 infected in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 26001344]
HEL	EC₅₀	0.93 μM Compound: Cidofovir	Antiviral activity against HSV1 KOS infected in HEL cells by viral CPE assay Antiviral activity against HSV1 KOS infected in HEL cells by viral CPE assay	[PMID: 22858222]
HEL	EC₅₀	0.94 μM Compound: 2, (S)-HPMPC	Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as protection against virus-induced cytopathicity Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as protection against virus-induced cytopathicity	[PMID: 21565516]
HEL	EC₅₀	0.94 μM Compound: HPMPC	Antiviral activity against Cytomegalovirus Davis infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity measured after 6 to 7 days Antiviral activity against Cytomegalovirus Davis infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity measured after 6 to 7 days	[PMID: 32676147]
HEL	EC₅₀	1 μM Compound: CDF	Antiviral activity against HSV2 G in human HEL cells assessed as protection against virus-induced cytopathicity Antiviral activity against HSV2 G in human HEL cells assessed as protection against virus-induced cytopathicity	[PMID: 19281225]
HEL	EC₅₀	1 μM Compound: CDF	Antiviral activity against thymidine kinase deficient and acyclovir resistant HSV1 KOS in human HEL cells assessed as protection against virus-induced cytopathicity Antiviral activity against thymidine kinase deficient and acyclovir resistant HSV1 KOS in human HEL cells assessed as protection against virus-induced cytopathicity	[PMID: 19281225]
HEL	EC₅₀	1 μM Compound: Cidofovir	Effective concentration required to inhibit HCMV Davis strain-induced cytopathicity in human embryonic lung (HEL) fibroblast cell cultures at day 7 of postinfection Effective concentration required to inhibit HCMV Davis strain-induced cytopathicity in human embryonic lung (HEL) fibroblast cell cultures at day 7 of postinfection	[PMID: 15027877]
HEL	EC₅₀	1 μM Compound: Cidofovir	Effective concentration required to inhibit human cytomegalo virus Davis induced cytopathicity in HEL fibroblast cell line after 7 days of postinfection Effective concentration required to inhibit human cytomegalo virus Davis induced cytopathicity in HEL fibroblast cell line after 7 days of postinfection	[PMID: 15801851]
HEL	EC₅₀	1 μM Compound: Cidofovir	Antiviral activity against Cytomegalovirus AD169 infected in HEL cells assessed as reduction of viral plaque formation Antiviral activity against Cytomegalovirus AD169 infected in HEL cells assessed as reduction of viral plaque formation	[PMID: 20064723]
HEL	EC₅₀	1 μM Compound: Cidofovir	Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as reduction in virus-induced cytopathicity Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as reduction in virus-induced cytopathicity	[PMID: 22578783]
HEL	EC₅₀	1 μM Compound: Cidofovir	Antiviral activity against human Cytomegalovirus AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathicity after Antiviral activity against human Cytomegalovirus AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathicity after	[PMID: 23911854]
HEL	EC₅₀	1 μM Compound: Cidofovir	Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity	[PMID: 23911856]
HEL	EC₅₀	1 μM Compound: Cidofovir	Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 26001344]
HEL	EC₅₀	1 μM Compound: Cidofovir	Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 26001344]
HEL	EC₅₀	1 μM Compound: HPMPC, Cidofovir	Antiviral activity against cidofovir HCMV AD169 clone 5 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against cidofovir HCMV AD169 clone 5 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 19226140]
HEL	EC₅₀	1.02 μM Compound: Cidofovir	Antiviral activity against Cytomegalovirus Davis infected in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Cytomegalovirus Davis infected in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 26001344]
HEL	EC₅₀	1.1 μM Compound: Cidofovir	Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as reduction in virus-induced cytopathicity Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as reduction in virus-induced cytopathicity	[PMID: 22578783]
HEL	EC₅₀	1.2 μM Compound: (S)-CDV, HPMPC	Antiviral activity against HCMV AD169/Davis infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days Antiviral activity against HCMV AD169/Davis infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days	[PMID: 21128666]
HEL	EC₅₀	1.2 μM Compound: Cidofovir	Antiviral activity against thymidine kinase-deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against thymidine kinase-deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 26001344]
HEL	EC₅₀	1.2 μM Compound: Cidofovir	Antiviral activity against thymidine kinase-deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus plaque formation Antiviral activity against thymidine kinase-deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus plaque formation	[PMID: 27639368]
HEL	EC₅₀	1.33 μM Compound: Cidofovir	Antiviral activity against HSV2 G infected in HEL cells by viral CPE assay Antiviral activity against HSV2 G infected in HEL cells by viral CPE assay	[PMID: 22858222]
HEL	EC₅₀	1.37 μM Compound: Cidofovir	Antiviral activity against HCMV AD169 infected in HEL cells by viral CPE assay Antiviral activity against HCMV AD169 infected in HEL cells by viral CPE assay	[PMID: 22858222]
HEL	EC₅₀	1.4 μM Compound: Cidofovir	Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 21232828]
HEL	EC₅₀	1.43 μM Compound: 2, (S)-HPMPC	Antiviral activity against Human herpesvirus 2 G infected in HEL cells assessed as protection against virus-induced cytopathicity Antiviral activity against Human herpesvirus 2 G infected in HEL cells assessed as protection against virus-induced cytopathicity	[PMID: 21565516]
HEL	EC₅₀	1.5 μM Compound: Cidofovir	Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 23099097]
HEL	EC₅₀	1.5 μM Compound: Cidofovir	Antiviral activity against thymidine kinase deficient and acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against thymidine kinase deficient and acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 23099097]
HEL	EC₅₀	1.5 μM Compound: Cidofovir	Antiviral activity against Human herpesvirus 2 strain G infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay Antiviral activity against Human herpesvirus 2 strain G infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay	[PMID: 32214762]
HEL	EC₅₀	1.53 μg/mL Compound: (S)-HPMPC, cidofovir	Antiviral activity against adenovirus 2 in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against adenovirus 2 in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 17298047]
HEL	EC₅₀	1.6 μM Compound: 2, (S)-HPMPC	Antiviral activity against Human herpesvirus 1 KOS infected in HEL cells assessed as protection against virus-induced cytopathicity Antiviral activity against Human herpesvirus 1 KOS infected in HEL cells assessed as protection against virus-induced cytopathicity	[PMID: 21565516]
HEL	EC₅₀	1.6 μM Compound: Cidofovir	Antiviral activity against human cytomegalovirus AD169 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 7 days post infection Antiviral activity against human cytomegalovirus AD169 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 7 days post infection	[PMID: 19339082]
HEL	EC₅₀	1.74 μM Compound: HPMPC	Antiviral activity against Cytomegalovirus AD169 infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity measured after 6 to 7 days Antiviral activity against Cytomegalovirus AD169 infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity measured after 6 to 7 days	[PMID: 32676147]
HEL	EC₅₀	1.75 μM Compound: Cidofovir	Antiviral activity against thymidine kinase negative and ACV resistant HSV1 KOS infected in HEL cells by viral CPE assay Antiviral activity against thymidine kinase negative and ACV resistant HSV1 KOS infected in HEL cells by viral CPE assay	[PMID: 22858222]
HEL	EC₅₀	1.84 μM Compound: Cidofovir	Antiviral activity against Cytomegalovirus Davis infected in human HEL cells assessed as reduction of plaque formation Antiviral activity against Cytomegalovirus Davis infected in human HEL cells assessed as reduction of plaque formation	[PMID: 23811093]
HEL	EC₅₀	10 μM Compound: Cidofovir	Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay	10.1007/s00044-009-9248-y
HEL	EC₅₀	10 μM Compound: Cidofovir	Antiviral activity against Vaccinia virus infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis Antiviral activity against Vaccinia virus infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis	[PMID: 21696963]
HEL	EC₅₀	10 μM Compound: Cidofovir	Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days	[PMID: 22459876]
HEL	EC₅₀	10 μM Compound: Cidofovir	Antiviral activity against Vaccinia virus Lederle infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity Antiviral activity against Vaccinia virus Lederle infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity	[PMID: 23911856]
HEL	EC₅₀	10 μM Compound: Cidofovir	Antiviral activity against Human adenovirus 2 infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Human adenovirus 2 infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 27742238]
HEL	EC₅₀	10 μM Compound: Cidofovir	Antiviral activity against Vaccinia virus infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay Antiviral activity against Vaccinia virus infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay	[PMID: 32214762]
HEL	EC₅₀	100 μM Compound: Cidofovir	Antiviral activity against thymidine kinase deficient Varicella zoster virus 07/1 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 5 days Antiviral activity against thymidine kinase deficient Varicella zoster virus 07/1 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 5 days	[PMID: 19339082]
HEL	EC₅₀	10 μg/mL Compound: cidofovir	Antiviral activity against Vaccinia virus infected in in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days Antiviral activity against Vaccinia virus infected in in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days	[PMID: 19419804]
HEL	EC₅₀	12.6 μg/mL Compound: Cidofovir	Antiviral activity against thymidine kinase deficient Varicella Zoster Virus 07/1 infected in HEL cells assessed as reduction in virus plaque formation Antiviral activity against thymidine kinase deficient Varicella Zoster Virus 07/1 infected in HEL cells assessed as reduction in virus plaque formation	[PMID: 19324473]
HEL	EC₅₀	14 μM Compound: Cidofovir	Antiviral activity against Vaccinia virus Lederie infected in HEL cells by viral CPE assay Antiviral activity against Vaccinia virus Lederie infected in HEL cells by viral CPE assay	[PMID: 22858222]
HEL	EC₅₀	17 μM Compound: Cidofovir	Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 23811093]
HEL	EC₅₀	2 μM Compound: (S)-CDV, HPMPC	Antiviral activity against HSV2 G infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days Antiviral activity against HSV2 G infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days	[PMID: 21128666]
HEL	EC₅₀	2 μM Compound: 2, (S)-HPMPC	Antiviral activity against acyclovir-resistant Human herpesvirus 1 KOS infected in HEL cells assessed as protection against virus-induced cytopathicity Antiviral activity against acyclovir-resistant Human herpesvirus 1 KOS infected in HEL cells assessed as protection against virus-induced cytopathicity	[PMID: 21565516]
HEL	EC₅₀	2 μM Compound: CDF	Antiviral activity against HSV1 KOS in human HEL cells assessed as protection against virus-induced cytopathicity Antiviral activity against HSV1 KOS in human HEL cells assessed as protection against virus-induced cytopathicity	[PMID: 19281225]
HEL	EC₅₀	2 μM Compound: Cidofovir	Antiviral activity against Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis Antiviral activity against Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis	[PMID: 21696963]
HEL	EC₅₀	2 μM Compound: Cidofovir	Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis	[PMID: 21696963]
HEL	EC₅₀	2 μM Compound: Cidofovir	Antiviral activity against acyclovir-resistant TK-deficient Herpes simplex virus-1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis Antiviral activity against acyclovir-resistant TK-deficient Herpes simplex virus-1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis	[PMID: 21696963]
HEL	EC₅₀	2 μM Compound: Cidofovir	Antiviral activity against thymidine kinase-deficient acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days Antiviral activity against thymidine kinase-deficient acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days	[PMID: 22459876]
HEL	EC₅₀	2 μM Compound: Cidofovir	Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 23811093]
HEL	EC₅₀	2 μM Compound: Cidofovir	Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 23811093]
HEL	EC₅₀	2 μM Compound: Cidofovir	Antiviral activity against TK-negative Herpes simplex virus 1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against TK-negative Herpes simplex virus 1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 23811093]
HEL	EC₅₀	2 μM Compound: Cidofovir	Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity	[PMID: 23911856]
HEL	EC₅₀	2 μM Compound: Cidofovir	Antiviral activity against thymidine kinase negative acyclovir positive Herpes simplex virus-1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity Antiviral activity against thymidine kinase negative acyclovir positive Herpes simplex virus-1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity	[PMID: 23911856]
HEL	EC₅₀	2.2 μg/mL Compound: (S)-HPMPC, cidofovir	Antiviral activity against (S)-3-hydroxy-2-phosphonomethoxypropyl cytosine-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against (S)-3-hydroxy-2-phosphonomethoxypropyl cytosine-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 18707089]
HEL	EC₅₀	2.5 μM Compound: (S)-CDV, HPMPC	Antiviral activity against acyclovir-resistant thymidine kinase deficient HSV1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days Antiviral activity against acyclovir-resistant thymidine kinase deficient HSV1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days	[PMID: 21128666]
HEL	EC₅₀	2.6 μg/mL Compound: (S)-HPMPC, cidofovir	Antiviral activity against vaccinia virus Lederle in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against vaccinia virus Lederle in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 17298047]
HEL	EC₅₀	20 μM Compound: CDF	Antiviral activity against Vaccinia virus Lederle in human HEL cells assessed as protection against virus-induced cytopathicity Antiviral activity against Vaccinia virus Lederle in human HEL cells assessed as protection against virus-induced cytopathicity	[PMID: 19281225]
HEL	EC₅₀	21 μM Compound: Cidofovir	Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 23099097]
HEL	EC₅₀	22 μM Compound: Cidofovir	Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis	[PMID: 23603046]
HEL	EC₅₀	22 μM Compound: Cidofovir	Antiviral activity against Vaccinia virus infected in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Vaccinia virus infected in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 26001344]
HEL	EC₅₀	25 μM Compound: Cidofovir	Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 27742238]
HEL	EC₅₀	2 μg/mL Compound: Cidofovir	Antiviral activity against HSV2 G infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days Antiviral activity against HSV2 G infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days	[PMID: 18851889]
HEL	EC₅₀	2 μg/mL Compound: Cidofovir	Antiviral activity against thymidine kinase-deficient acyclovir-resistant HSV1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days Antiviral activity against thymidine kinase-deficient acyclovir-resistant HSV1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days	[PMID: 18851889]
HEL	EC₅₀	2 μg/mL Compound: Cidofovir	Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days	[PMID: 20724039]
HEL	EC₅₀	2 μg/mL Compound: Cidofovir	Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days	[PMID: 20724039]
HEL	EC₅₀	2 μg/mL Compound: HPMPC, cidofovir	Antiviral activity against adenovirus type 2 in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against adenovirus type 2 in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17948980]
HEL	EC₅₀	3 μM Compound: Cidofovir	Antiviral activity against Human herpesvirus 1 strain KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay Antiviral activity against Human herpesvirus 1 strain KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay	10.1007/s00044-009-9248-y
HEL	EC₅₀	3.09 μg/mL Compound: HPMPC, cidofovir	Antiviral activity against vaccinia virus Lederle in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against vaccinia virus Lederle in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17948980]
HEL	EC₅₀	3.1 μM Compound: Cidofovir	Antiviral activity against Cytomegalovirus AD-169 infected in human HEL cells assessed as reduction in virus plaque formation Antiviral activity against Cytomegalovirus AD-169 infected in human HEL cells assessed as reduction in virus plaque formation	[PMID: 23911856]
HEL	EC₅₀	3.1 μg/mL Compound: (S)-HPMPC, cidofovir	Antiviral activity against (S)-3-hydroxy-2-phosphonomethoxypropyl adenine-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against (S)-3-hydroxy-2-phosphonomethoxypropyl adenine-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 18707089]
HEL	EC₅₀	3.5 μM Compound: (S)-CDV, HPMPC	Antiviral activity against HSV1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days Antiviral activity against HSV1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days	[PMID: 21128666]
HEL	EC₅₀	3 μg/mL Compound: Cidofovir	Antiviral activity against HSV1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days Antiviral activity against HSV1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days	[PMID: 18851889]
HEL	EC₅₀	3 μg/mL Compound: Cidofovir	Antiviral activity against acyclovir-resistant TK deficient Herpes simplex virus-1 KOS infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days Antiviral activity against acyclovir-resistant TK deficient Herpes simplex virus-1 KOS infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days	[PMID: 20724039]
HEL	EC₅₀	3 μg/mL Compound: cidofovir	Antiviral activity against HSV1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days Antiviral activity against HSV1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days	[PMID: 19419804]
HEL	EC₅₀	5 μM Compound: Cidofovir	Antiviral activity against Human herpesvirus 2 strain G infected HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay Antiviral activity against Human herpesvirus 2 strain G infected HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay	10.1007/s00044-009-9248-y
HEL	EC₅₀	5 μM Compound: Cidofovir	Antiviral activity against acyclovir-resistant TK-deficient Hepres simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay Antiviral activity against acyclovir-resistant TK-deficient Hepres simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay	10.1007/s00044-009-9248-y
HEL	EC₅₀	5 μM Compound: Cidofovir	Antiviral activity against Human herpesvirus 1 strain KOS infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay Antiviral activity against Human herpesvirus 1 strain KOS infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay	[PMID: 32214762]
HEL	EC₅₀	5 μg/mL Compound: cidofovir	Antiviral activity against HSV2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days Antiviral activity against HSV2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days	[PMID: 19419804]
HEL	EC₅₀	5 μg/mL Compound: cidofovir	Antiviral activity against thymidine kinase-deficient ACV-resistant HSV1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days Antiviral activity against thymidine kinase-deficient ACV-resistant HSV1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days	[PMID: 19419804]
HEL	EC₅₀	6 μM Compound: (S)-CDV, HPMPC	Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days	[PMID: 21128666]
HEL	EC₅₀	6 μM Compound: Cidofovir	Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 21232828]
HEL	EC₅₀	6 μM Compound: Cidofovir	Antiviral activity against acyclovir-resistant thymidine kinase negative Human herpesvirus 1 strain KOS infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay Antiviral activity against acyclovir-resistant thymidine kinase negative Human herpesvirus 1 strain KOS infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay	[PMID: 32214762]
HEL	EC₅₀	7 μM Compound: 2, (S)-HPMPC	Antiviral activity against Vaccinia virus infected in HEL cells assessed as protection against virus-induced cytopathicity Antiviral activity against Vaccinia virus infected in HEL cells assessed as protection against virus-induced cytopathicity	[PMID: 21565516]
HEL	EC₅₀	7 μg/mL Compound: Cidofovir	Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days	[PMID: 18851889]
HEL	EC₅₀	8 μg/mL Compound: Cidofovir	Antiviral activity against Vaccinia virus infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days Antiviral activity against Vaccinia virus infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days	[PMID: 20724039]
HEL	EC₅₀	> 250 μM Compound: CDF	Antiviral activity against VSV in human HEL cells assessed as protection against virus-induced cytopathicity Antiviral activity against VSV in human HEL cells assessed as protection against virus-induced cytopathicity	[PMID: 19281225]
HEL	EC₅₀	> 250 μM Compound: Cidofovir	Antiviral activity against Vesicular stomatitis virus infected HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay Antiviral activity against Vesicular stomatitis virus infected HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay	10.1007/s00044-009-9248-y
HEL	EC₅₀	> 250 μM Compound: Cidofovir	Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days	[PMID: 22459876]
HEL	EC₅₀	> 250 μM Compound: Cidofovir	Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 23099097]
HEL	EC₅₀	> 250 μM Compound: Cidofovir	Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 23811093]
HEL	EC₅₀	> 250 μM Compound: Cidofovir	Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity	[PMID: 23911856]
HEL	EC₅₀	> 250 μM Compound: Cidofovir	Antiviral activity against Vesicular stomatitis virus infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay Antiviral activity against Vesicular stomatitis virus infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay	[PMID: 32214762]
HEL	EC₅₀	> 250 μg/mL Compound: Cidofovir	Antiviral activity against VSV infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days Antiviral activity against VSV infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days	[PMID: 18851889]
HEL	EC₅₀	> 250 μg/mL Compound: Cidofovir	Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days	[PMID: 20724039]
HEL	EC₅₀	> 250 μg/mL Compound: Cidofovir	Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay	[PMID: 20971531]
HEL	EC₅₀	> 250 μg/mL Compound: Cidofovir	Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay	[PMID: 20971531]
HEL	EC₅₀	> 250 μg/mL Compound: Cidofovir	Antiviral activity against thymidine kinase deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay Antiviral activity against thymidine kinase deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay	[PMID: 20971531]
HEL	EC₅₀	> 250 μg/mL Compound: cidofovir	Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days	[PMID: 19419804]
HEL	EC₅₀	> 31.5 μg/mL Compound: HPMPC, cidofovir	Antiviral activity against VSV in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against VSV in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17948980]
HEL	IC₅₀	0.055 μg/mL Compound: (S)-HPMPC	Evaluated in vitro for antiviral activity in human embryonic lung (HEL) cell cultures against TK- VZV strain 07/1 Evaluated in vitro for antiviral activity in human embryonic lung (HEL) cell cultures against TK- VZV strain 07/1	10.1016/0960-894X(95)00278-2
HEL	IC₅₀	0.05 μg/mL Compound: (S)-HPMPC	Evaluated in vitro for antiviral activity in human embryonic lung (HEL) cell cultures against TK- Varicella-Zoster virus (VZV) strain YS/R Evaluated in vitro for antiviral activity in human embryonic lung (HEL) cell cultures against TK- Varicella-Zoster virus (VZV) strain YS/R	10.1016/0960-894X(95)00278-2
HEL	IC₅₀	0.065 μg/mL Compound: (S)-HPMPC	Evaluated in vitro for antiviral activity in human embryonic lung (HEL) cell cultures against TK+ VZV strain OKA Evaluated in vitro for antiviral activity in human embryonic lung (HEL) cell cultures against TK+ VZV strain OKA	10.1016/0960-894X(95)00278-2
HEL	IC₅₀	0.06 μg/mL Compound: (S)-HPMPC	Evaluated in vitro for antiviral activity in human embryonic lung (HEL) cell cultures against cytomegalovirus (CMV) strain AD-169 Evaluated in vitro for antiviral activity in human embryonic lung (HEL) cell cultures against cytomegalovirus (CMV) strain AD-169	10.1016/0960-894X(95)00278-2
HEL	IC₅₀	0.075 μg/mL Compound: (S)-HPMPC	Evaluated in vitro for antiviral activity in human embryonic lung (HEL) cell cultures against cytomegalovirus (CMV) strain Davis Evaluated in vitro for antiviral activity in human embryonic lung (HEL) cell cultures against cytomegalovirus (CMV) strain Davis	10.1016/0960-894X(95)00278-2
HEL	IC₅₀	0.09 μg/mL Compound: (S)-HPMPC	Evaluated in vitro for antiviral activity in human embryonic lung (HEL) cell cultures against TK+ Varicella-Zoster virus (VZV) strain YS Evaluated in vitro for antiviral activity in human embryonic lung (HEL) cell cultures against TK+ Varicella-Zoster virus (VZV) strain YS	10.1016/0960-894X(95)00278-2
HEL 299	CC₅₀	192 μM Compound: 1a, HPMPC	Cytotoxicity against HEL299 cells after 4 days by Z1 Coulter counting analysis Cytotoxicity against HEL299 cells after 4 days by Z1 Coulter counting analysis	[PMID: 17893157]
HEL 299	EC₅₀	6.6 μM Compound: 1a, HPMPC	Antiviral activity against Camelpox virus CML14 infected in HEL299 cells assessed as inhibition of virus-induced cytopathic effect after 6 days by Giemsa staining Antiviral activity against Camelpox virus CML14 infected in HEL299 cells assessed as inhibition of virus-induced cytopathic effect after 6 days by Giemsa staining	[PMID: 17893157]
HEL 299	EC₅₀	8.2 μM Compound: 1a, HPMPC	Antiviral activity against Camelpox virus CML1 infected in HEL299 cells assessed as inhibition of virus-induced cytopathic effect after 6 days by Giemsa staining Antiviral activity against Camelpox virus CML1 infected in HEL299 cells assessed as inhibition of virus-induced cytopathic effect after 6 days by Giemsa staining	[PMID: 17893157]
HFF	CC₅₀	100 μM Compound: cidofovir	Cytotoxicity against HFF cells by alamar blue assay Cytotoxicity against HFF cells by alamar blue assay	[PMID: 17329103]
HFF	CC₅₀	> 100 μM Compound: 1, HPMPC, Vistide	Cytotoxicity against HFF cells Cytotoxicity against HFF cells	[PMID: 21641218]
HFF	CC₅₀	> 100 μM Compound: CDV	Cytotoxicity against HFF after 3 days by MTS assay Cytotoxicity against HFF after 3 days by MTS assay	[PMID: 19770274]
HFF	CC₅₀	> 100 μM Compound: Cidofovir	Cytotoxicity against BK polyomavirus Gardner infected-human HFF cells assessed as reduction in cell viability after 7 days by cell titer-glo assay Cytotoxicity against BK polyomavirus Gardner infected-human HFF cells assessed as reduction in cell viability after 7 days by cell titer-glo assay	[PMID: 27624078]
HFF	CC₅₀	> 300 μM Compound: cidofovir	Cytotoxicity against HFF cell line by neutral red toxicity assay Cytotoxicity against HFF cell line by neutral red toxicity assay	[PMID: 16722657]
HFF	CC₅₀	> 317 μM Compound: CDV	Half-maximal cytotoxic concentration in human foreskin fibroblast (HFF) cells Half-maximal cytotoxic concentration in human foreskin fibroblast (HFF) cells	[PMID: 15828843]
HFF	CC₅₀	> 317 μM Compound: CDV	Half-maximal cytotoxic concentration in human foreskin fibroblast (HFF) cells Half-maximal cytotoxic concentration in human foreskin fibroblast (HFF) cells	[PMID: 15828843]
HFF	CC₅₀	> 317 μM Compound: CDV	Cytotoxicity against HFF cell Cytotoxicity against HFF cell	[PMID: 16539388]
HFF	CC₅₀	> 317 μM Compound: CDV	Cytotoxicity against HFF cells Cytotoxicity against HFF cells	[PMID: 17116683]
HFF	CC₅₀	> 317 μM Compound: CDV	Cytotoxicity against HFF cells after 7 days by neutral red assay Cytotoxicity against HFF cells after 7 days by neutral red assay	[PMID: 17724153]
HFF	CC₅₀	> 317 μM Compound: CDV	Cytotoxicity against HFF cells after 7 days Cytotoxicity against HFF cells after 7 days	[PMID: 17846137]
HFF	CC₅₀	> 317 μM Compound: CDV	Cytotoxicity against HFF after 7 days by neutral red uptake assay Cytotoxicity against HFF after 7 days by neutral red uptake assay	[PMID: 19029322]
HFF	CC₅₀	> 317 μM Compound: CDV	Cytotoxicity against human HFF cells infected with Cowpox virus (Brighton Red) assessed as viable cells by neutral red uptake assay Cytotoxicity against human HFF cells infected with Cowpox virus (Brighton Red) assessed as viable cells by neutral red uptake assay	[PMID: 21376429]
HFF	CC₅₀	> 317 μM Compound: CDV	Cytotoxicity against human HFF cells infected with Vaccinia virus Copenhagen assessed as viable cells by neutral red uptake assay Cytotoxicity against human HFF cells infected with Vaccinia virus Copenhagen assessed as viable cells by neutral red uptake assay	[PMID: 21376429]
HFF	CC₅₀	> 317 μM Compound: cidofovir	Cytotoxicity against human HFF cells by neutral red uptake Cytotoxicity against human HFF cells by neutral red uptake	[PMID: 16603351]
HFF	CC₅₀	> 317 μM Compound: cidofovir	Cytotoxicity against HFF cells by neutral red uptake assay Cytotoxicity against HFF cells by neutral red uptake assay	[PMID: 16821766]
HFF	EC₅₀	0.22 μM Compound: CDV	Antiviral activity against Cytomegalovirus CMV T2211 infected in HFF cells by SEAP reporter gene assay Antiviral activity against Cytomegalovirus CMV T2211 infected in HFF cells by SEAP reporter gene assay	[PMID: 17709468]
HFF	EC₅₀	0.27 μM Compound: CDV	Antiviral activity against Cytomegalovirus CMV T2258 with UL97 C592G mutant infected in HFF cells by SEAP reporter gene assay Antiviral activity against Cytomegalovirus CMV T2258 with UL97 C592G mutant infected in HFF cells by SEAP reporter gene assay	[PMID: 17709468]
HFF	EC₅₀	0.37 μM Compound: CDV	Antiviral activity against Cytomegalovirus CMV T2798 with pol T813S UL97 C592G double mutant infected in HFF cells by SEAP reporter gene assay Antiviral activity against Cytomegalovirus CMV T2798 with pol T813S UL97 C592G double mutant infected in HFF cells by SEAP reporter gene assay	[PMID: 17709468]
HFF	EC₅₀	0.42 μM Compound: CDV	Antiviral activity against Cytomegalovirus CMV T2417 with pol A809V mutant infected in HFF cells by SEAP reporter gene assay Antiviral activity against Cytomegalovirus CMV T2417 with pol A809V mutant infected in HFF cells by SEAP reporter gene assay	[PMID: 17709468]
HFF	EC₅₀	0.45 μM Compound: CDV	Antiviral activity against Cytomegalovirus CMV T2784 with pol A809V UL97 C592G double mutant infected in HFF cells by SEAP reporter gene assay Antiviral activity against Cytomegalovirus CMV T2784 with pol A809V UL97 C592G double mutant infected in HFF cells by SEAP reporter gene assay	[PMID: 17709468]
HFF	EC₅₀	0.58 μM Compound: CDV	Antiviral activity against Cytomegalovirus CMV T2420 with pol G841A mutant infected in HFF cells by SEAP reporter gene assay Antiviral activity against Cytomegalovirus CMV T2420 with pol G841A mutant infected in HFF cells by SEAP reporter gene assay	[PMID: 17709468]
HFF	EC₅₀	0.6 μM Compound: CDV	Antiviral activity against Cytomegalovirus CMV T2542 with pol T813S mutant infected in HFF cells by SEAP reporter gene assay Antiviral activity against Cytomegalovirus CMV T2542 with pol T813S mutant infected in HFF cells by SEAP reporter gene assay	[PMID: 17709468]
HFF	EC₅₀	0.67 μM Compound: CDV	Antiviral activity against Cytomegalovirus CMV 2817 with pol G841A UL97 C592G double mutant infected in HFF cells by SEAP reporter gene assay Antiviral activity against Cytomegalovirus CMV 2817 with pol G841A UL97 C592G double mutant infected in HFF cells by SEAP reporter gene assay	[PMID: 17709468]
HFF	EC₅₀	1.1 μM Compound: Cidofovir	Antiviral activity against BK polyomavirus Gardner infected in human HFF cells assessed as reduction in DNA copy number after 7 days by PCR analysis Antiviral activity against BK polyomavirus Gardner infected in human HFF cells assessed as reduction in DNA copy number after 7 days by PCR analysis	[PMID: 27624078]
HFF	EC₅₀	1.2 μM Compound: 2, (S)-HPMPC	Antiviral activity against Human cytomegalovirus AD169 infected in HFF cells assessed as protection against virus-induced cytopathicity Antiviral activity against Human cytomegalovirus AD169 infected in HFF cells assessed as protection against virus-induced cytopathicity	[PMID: 21565516]
HFF	EC₅₀	10 μM Compound: CDV, cidofovir	Antiviral activity against TK+ Cowpox virus Delta crmA in HFF cells after 48 hrs by beta-galactosidase assay Antiviral activity against TK+ Cowpox virus Delta crmA in HFF cells after 48 hrs by beta-galactosidase assay	[PMID: 17325220]
HFF	EC₅₀	11 μM Compound: CDV, cidofovir	Antiviral activity against Vaccinia virus in HFF cells after 1 hr by plaque reduction assay Antiviral activity against Vaccinia virus in HFF cells after 1 hr by plaque reduction assay	[PMID: 17325220]
HFF	EC₅₀	16 μM Compound: CDV, cidofovir	Antiviral activity against TK- Cowpox virus TK:GFP lacZ in HFF cells after 48 hrs by beta-galactosidase assay Antiviral activity against TK- Cowpox virus TK:GFP lacZ in HFF cells after 48 hrs by beta-galactosidase assay	[PMID: 17325220]
HFF	EC₅₀	20 μM Compound: cidofovir	Antiviral activity against Vaccinia virus Copenhagen in HFF cells assessed as reduction in plaque formation Antiviral activity against Vaccinia virus Copenhagen in HFF cells assessed as reduction in plaque formation	[PMID: 16603351]
HFF	EC₅₀	24 μM Compound: cidofovir	Antiviral activity against vaccinia virus in HFF cells by plaque reduction assay Antiviral activity against vaccinia virus in HFF cells by plaque reduction assay	[PMID: 16821766]
HFF	EC₅₀	25.3 μM Compound: CDV	Antiviral activity against Vaccinia virus Copenhagen replication in HFF cells Antiviral activity against Vaccinia virus Copenhagen replication in HFF cells	[PMID: 16539388]
HFF	EC₅₀	26 μM Compound: CDV	Antiviral activity against Vaccinia virus Copenhagen in HFF cells assessed as reduction of viral replication after 3 days Antiviral activity against Vaccinia virus Copenhagen in HFF cells assessed as reduction of viral replication after 3 days	[PMID: 17846137]
HFF	EC₅₀	27 μM Compound: CDV	Effective concentration required to inhibit vaccinia virus plaque formation in human foreskin fibroblast (HFF) cells Effective concentration required to inhibit vaccinia virus plaque formation in human foreskin fibroblast (HFF) cells	[PMID: 15828843]
HFF	EC₅₀	29 μM Compound: CDV	Antiviral activity against Vaccinia virus WR in HFF cells assessed as reduction of viral replication after 3 days Antiviral activity against Vaccinia virus WR in HFF cells assessed as reduction of viral replication after 3 days	[PMID: 17846137]
HFF	EC₅₀	29.2 μM Compound: CDV	Antiviral activity against Vaccinia virus Copenhagen infected HFF cells Antiviral activity against Vaccinia virus Copenhagen infected HFF cells	[PMID: 17116683]
HFF	EC₅₀	29.2 μM Compound: CDV	Antiviral activity against Vaccinia virus Copenhagen in HFF cells assessed as reduction plaque formation after 3 days Antiviral activity against Vaccinia virus Copenhagen in HFF cells assessed as reduction plaque formation after 3 days	[PMID: 17724153]
HFF	EC₅₀	3.2 μM Compound: cidofovir	Antiviral activity against Vaccinia virus Copenhagen in HFF cells assessed as reduction in cytopathogenicity Antiviral activity against Vaccinia virus Copenhagen in HFF cells assessed as reduction in cytopathogenicity	[PMID: 16603351]
HFF	EC₅₀	3.2 μM Compound: cidofovir	Antiviral activity against vaccinia virus in HFF cells by cytopathogenic effect assay Antiviral activity against vaccinia virus in HFF cells by cytopathogenic effect assay	[PMID: 16821766]
HFF	EC₅₀	3.3 μM Compound: cidofovir	Antiviral activity against TK+ cowpox virus delta crmA in HFF cells Antiviral activity against TK+ cowpox virus delta crmA in HFF cells	[PMID: 16821766]
HFF	EC₅₀	30.7 μM Compound: CDV	Antiviral activity against Cowpox virus Brighton replication in HFF cells Antiviral activity against Cowpox virus Brighton replication in HFF cells	[PMID: 16539388]
HFF	EC₅₀	32 μM Compound: CDV, cidofovir	Antiviral activity against Cowpox virus Brighton in HFF cells after 1 hr by plaque reduction assay Antiviral activity against Cowpox virus Brighton in HFF cells after 1 hr by plaque reduction assay	[PMID: 17325220]
HFF	EC₅₀	32 μM Compound: cidofovir	Antiviral activity against Cowpox virus Brighton in HFF cells assessed as reduction in plaque formation Antiviral activity against Cowpox virus Brighton in HFF cells assessed as reduction in plaque formation	[PMID: 16603351]
HFF	EC₅₀	33 μM Compound: CDV	Antiviral activity against Vaccinia virus WR infected HFF cells Antiviral activity against Vaccinia virus WR infected HFF cells	[PMID: 17116683]
HFF	EC₅₀	33 μM Compound: CDV	Antiviral activity against Vaccinia virus WR in HFF cells assessed as reduction plaque formation after 3 days Antiviral activity against Vaccinia virus WR in HFF cells assessed as reduction plaque formation after 3 days	[PMID: 17724153]
HFF	EC₅₀	35 μM Compound: CDV	Antiviral activity against Cowpox virus Brighton in HFF cells assessed as reduction of viral replication after 3 days Antiviral activity against Cowpox virus Brighton in HFF cells assessed as reduction of viral replication after 3 days	[PMID: 17846137]
HFF	EC₅₀	38 μM Compound: CDV	Effective concentration required to inhibit cowpox virus plaque formation in human foreskin fibroblast (HFF) cells Effective concentration required to inhibit cowpox virus plaque formation in human foreskin fibroblast (HFF) cells	[PMID: 15828843]
HFF	EC₅₀	4.8 μM Compound: cidofovir	Antiviral activity against Vaccinia virus in HFF cells Antiviral activity against Vaccinia virus in HFF cells	[PMID: 16275078]
HFF	EC₅₀	40 μM Compound: cidofovir	Antiviral activity against cowpox virus in HFF cells by plaque reduction assay Antiviral activity against cowpox virus in HFF cells by plaque reduction assay	[PMID: 16821766]
HFF	EC₅₀	41.1 μM Compound: CDV	Antiviral activity against Cowpox virus Brighton infected HFF cells Antiviral activity against Cowpox virus Brighton infected HFF cells	[PMID: 17116683]
HFF	EC₅₀	41.1 μM Compound: CDV	Antiviral activity against Cowpox virus Brighton in HFF cells assessed as reduction plaque formation after 3 days Antiviral activity against Cowpox virus Brighton in HFF cells assessed as reduction plaque formation after 3 days	[PMID: 17724153]
HFF	EC₅₀	5 μM Compound: cidofovir	Antiviral activity against Cowpox virus in HFF cells Antiviral activity against Cowpox virus in HFF cells	[PMID: 16275078]
HFF	EC₅₀	5.2 μM Compound: cidofovir	Antiviral activity against TK- cowpox virus TK:GFP lacZ in HFF cells Antiviral activity against TK- cowpox virus TK:GFP lacZ in HFF cells	[PMID: 16821766]
HFF	EC₅₀	6.7 μM Compound: CDV	Antiviral activity against Cowpox virus (Brighton Red) infected in human HFF cells assessed as reduction in viral-induced cytopathic effect by neutral red uptake assay Antiviral activity against Cowpox virus (Brighton Red) infected in human HFF cells assessed as reduction in viral-induced cytopathic effect by neutral red uptake assay	[PMID: 21376429]
HFF	EC₅₀	6.9 μM Compound: cidofovir	Antiviral activity against vaccinia virus Copenhagen measured as cytopathogenicity in HFF cells Antiviral activity against vaccinia virus Copenhagen measured as cytopathogenicity in HFF cells	[PMID: 16722657]
HFF	EC₅₀	7.1 μM Compound: cidofovir	Antiviral activity against Cowpox virus Brighton in HFF cells assessed as reduction in cytopathogenicity Antiviral activity against Cowpox virus Brighton in HFF cells assessed as reduction in cytopathogenicity	[PMID: 16603351]
HFF	EC₅₀	8.3 μM Compound: cidofovir	Antiviral activity against cowpox virus Brighton measured as cytopathogenicity in HFF cells Antiviral activity against cowpox virus Brighton measured as cytopathogenicity in HFF cells	[PMID: 16722657]
HFF	EC₅₀	9 μM Compound: cidofovir	Antiviral activity against cowpox virus Brighton by plaque reduction in HFF cells Antiviral activity against cowpox virus Brighton by plaque reduction in HFF cells	[PMID: 16722657]
HFF	EC₅₀	9 μM Compound: cidofovir	Antiviral activity against vaccinia virus Copenhagen assessed as plaque reduction in HFF cells Antiviral activity against vaccinia virus Copenhagen assessed as plaque reduction in HFF cells	[PMID: 16722657]
HFF	EC₅₀	9.8 μM Compound: CDV	Antiviral activity against Vaccinia virus Copenhagen infected in human HFF cells assessed as reduction in viral-induced cytopathic effect by neutral red uptake assay Antiviral activity against Vaccinia virus Copenhagen infected in human HFF cells assessed as reduction in viral-induced cytopathic effect by neutral red uptake assay	[PMID: 21376429]
HFF	IC₅₀	0.11 μM Compound: 1, HPMPC, Vistide	Antiviral activity against Human cytomegalovirus Towne infected in HFF cells assessed as reduction in plaque formation after 10 days Antiviral activity against Human cytomegalovirus Towne infected in HFF cells assessed as reduction in plaque formation after 10 days	[PMID: 21641218]
HFF	IC₅₀	0.2 μM Compound: CDV	Antiviral activity against Human CMV T2211 in HFF cells by SEAP assay Antiviral activity against Human CMV T2211 in HFF cells by SEAP assay	[PMID: 17043128]
HFF	IC₅₀	0.28 μM Compound: 2, (S)-HPMPC, Cidofovir, CDV	Antiviral activity against HCMV Towne infected in HFF cells incubated for 10 days by plaque reduction assay Antiviral activity against HCMV Towne infected in HFF cells incubated for 10 days by plaque reduction assay	[PMID: 21812420]
HFF	IC₅₀	0.3 μM Compound: CDV	Antiviral activity against Human CMV T2233 in HFF cells by SEAP assay Antiviral activity against Human CMV T2233 in HFF cells by SEAP assay	[PMID: 17043128]
HFF	IC₅₀	0.3 μM Compound: CDV	Antiviral activity against Human CMV T2241 in HFF cells by SEAP assay Antiviral activity against Human CMV T2241 in HFF cells by SEAP assay	[PMID: 17043128]
HFF	IC₅₀	0.35 μM Compound: cidofovir	Antiviral activity against HCMV infected HFF cells after 5 days by dot blot assay Antiviral activity against HCMV infected HFF cells after 5 days by dot blot assay	[PMID: 17329103]
HFF	IC₅₀	0.7 μM Compound: CDV	Antiviral activity against Human CMV T2291 in HFF cells by SEAP assay Antiviral activity against Human CMV T2291 in HFF cells by SEAP assay	[PMID: 17043128]
HFF	IC₅₀	0.9 μM Compound: CDV	Antiviral activity against Human CMV AD169 in HFF cells by PRA Antiviral activity against Human CMV AD169 in HFF cells by PRA	[PMID: 17043128]
HFF	IC₅₀	1.9 μM Compound: CDV	Antiproliferative activity against HFF after 3 days by coulter counter assay Antiproliferative activity against HFF after 3 days by coulter counter assay	[PMID: 19029322]
HFF	IC₅₀	1.9 μM Compound: CDV	Antiproliferative activity against HFF after 3 days by Coulter counting analysis Antiproliferative activity against HFF after 3 days by Coulter counting analysis	[PMID: 19770274]
HFF	IC₅₀	100 μM Compound: 2, (S)-HPMPC, Cidofovir, CDV	Cytotoxicity against HFF cells after 48 hrs by visual cytotoxicity observation assay Cytotoxicity against HFF cells after 48 hrs by visual cytotoxicity observation assay	[PMID: 21812420]
HFF	IC₅₀	20 μM Compound: 1, HPMPC, Vistide	Antiviral activity against Vaccinia virus Copenhagen infected in HFF cells assessed as reduction in plaque formation after 3 days Antiviral activity against Vaccinia virus Copenhagen infected in HFF cells assessed as reduction in plaque formation after 3 days	[PMID: 21641218]
HFF	IC₅₀	20 μM Compound: 2, (S)-HPMPC, Cidofovir, CDV	Antiviral activity against Vaccinia virus Copenhagen infected in HFF cells incubated for 3 days by plaque reduction assay Antiviral activity against Vaccinia virus Copenhagen infected in HFF cells incubated for 3 days by plaque reduction assay	[PMID: 21812420]
HFF	IC₅₀	3.3 μM Compound: CDV	Antiviral activity against Human CMV T2291 in HFF cells by PRA Antiviral activity against Human CMV T2291 in HFF cells by PRA	[PMID: 17043128]
HFF	IC₅₀	30 μM Compound: 1, HPMPC, Vistide	Antiviral activity against Cowpox virus Brighton infected in HFF cells assessed as reduction in plaque formation after 3 days Antiviral activity against Cowpox virus Brighton infected in HFF cells assessed as reduction in plaque formation after 3 days	[PMID: 21641218]
HFF	IC₅₀	30 μM Compound: 2, (S)-HPMPC, Cidofovir, CDV	Antiviral activity against Cowpox virus Brighton infected in HFF cells incubated for 3 days by plaque reduction assay Antiviral activity against Cowpox virus Brighton infected in HFF cells incubated for 3 days by plaque reduction assay	[PMID: 21812420]
HFF	IC₅₀	4.7 μM Compound: CDV	Antiviral activity against Human CMV T2311 in HFF cells by SEAP assay Antiviral activity against Human CMV T2311 in HFF cells by SEAP assay	[PMID: 17043128]
HFF	IC₅₀	4.9 μM Compound: CDV	Antiviral activity against Human CMV T2293 in HFF cells by PRA Antiviral activity against Human CMV T2293 in HFF cells by PRA	[PMID: 17043128]
HFF	IC₅₀	5.2 μM Compound: CDV	Antiviral activity against Human CMV T2293 in HFF cells by SEAP assay Antiviral activity against Human CMV T2293 in HFF cells by SEAP assay	[PMID: 17043128]
HFF	IC₅₀	8.9 μM Compound: CDV	Antiviral activity against Human CMV T2311 in HFF cells by PRA Antiviral activity against Human CMV T2311 in HFF cells by PRA	[PMID: 17043128]
HFF	IC₅₀	> 100 μM Compound: cdv	Cytotoxicity against HFF cells Cytotoxicity against HFF cells	[PMID: 16814545]
HT-3	EC₅₀	> 100000 nM Compound: Cidofovir	Antiproliferative activity against HPV-non-transformed human HT3 cells after 7 days by SRB assay Antiproliferative activity against HPV-non-transformed human HT3 cells after 7 days by SRB assay	[PMID: 19398642]
HeLa	CC₅₀	244 μg/mL Compound: Cidofovir	Cytotoxicity against Varicella Zoster Virus infected human HeLa cells assessed as reduction in cell growth Cytotoxicity against Varicella Zoster Virus infected human HeLa cells assessed as reduction in cell growth	[PMID: 19324473]
HeLa	CC₅₀	50.8 μM Compound: Cidofovir	Cytotoxicity against human HeLa cells assessed as cell viability by colorimetric formazan-based MTS assay Cytotoxicity against human HeLa cells assessed as cell viability by colorimetric formazan-based MTS assay	[PMID: 22459876]
HeLa	CC₅₀	> 50 μg/mL Compound: Cidofovir	Cytotoxicity against Varicella Zoster Virus infected human HeLa cells assessed as change in cell morphology Cytotoxicity against Varicella Zoster Virus infected human HeLa cells assessed as change in cell morphology	[PMID: 19324473]
HeLa	EC₅₀	> 100000 nM Compound: Cidofovir	Antiproliferative activity against HPV-transformed human HeLa cells after 7 days by SRB assay Antiproliferative activity against HPV-transformed human HeLa cells after 7 days by SRB assay	[PMID: 19398642]
HeLa	EC₅₀	> 31.5 μg/mL Compound: HPMPC, cidofovir	Antiviral activity against Coxsackie virus B4 in HeLa cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Coxsackie virus B4 in HeLa cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17948980]
HeLa	EC₅₀	> 31.5 μg/mL Compound: HPMPC, cidofovir	Antiviral activity against RSV in HeLa cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against RSV in HeLa cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17948980]
HeLa	EC₅₀	> 31.5 μg/mL Compound: HPMPC, cidofovir	Antiviral activity against VSV in HeLa cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against VSV in HeLa cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17948980]
HeLa S3	EC₅₀	18.74 μM Compound: Cidofovir	Antiviral activity against Vaccinia virus IHD-J ATCC VR-156 infected in HeLaS3 cells after 3 to 5 days by plaque assay Antiviral activity against Vaccinia virus IHD-J ATCC VR-156 infected in HeLaS3 cells after 3 to 5 days by plaque assay	[PMID: 18852271]
HeLa S3	EC₅₀	20.61 μM Compound: Cidofovir	Antiviral activity against Vaccinia virus IHD-W ATCC VR-1441 infected in HeLaS3 cells after 3 to 5 days by plaque assay Antiviral activity against Vaccinia virus IHD-W ATCC VR-1441 infected in HeLaS3 cells after 3 to 5 days by plaque assay	[PMID: 18852271]
HeLa S3	EC₅₀	30.85 μM Compound: Cidofovir	Antiviral activity against Vaccinia virus WR harboring the HIV gag gene infected in HeLaS3 cells after 3 to 5 days by plaque assay Antiviral activity against Vaccinia virus WR harboring the HIV gag gene infected in HeLaS3 cells after 3 to 5 days by plaque assay	[PMID: 18852271]
HeLa S3	IC₅₀	38 μM Compound: Cidofovir	Antiviral activity against Vaccinia virus WR harboring the HIV gag gene infected in HeLaS3 cells assessed as inhibition of viral replication in hollow-fiber infection model by plaque assay Antiviral activity against Vaccinia virus WR harboring the HIV gag gene infected in HeLaS3 cells assessed as inhibition of viral replication in hollow-fiber infection model by plaque assay	[PMID: 18852271]
Jurkat	CC₅₀	100 μM Compound: cidofovir	Cytotoxicity against human Jurkat cells by alamar blue assay Cytotoxicity against human Jurkat cells by alamar blue assay	[PMID: 17329103]
Jurkat	IC₅₀	100 μM Compound: cdv	Cytotoxicity against human Jurkat cells Cytotoxicity against human Jurkat cells	[PMID: 16814545]
KB	CC₅₀	> 100 μM Compound: 1, HPMPC, Vistide	Cytotoxicity against human KB cells after 48 hrs by crystal violet staining technique Cytotoxicity against human KB cells after 48 hrs by crystal violet staining technique	[PMID: 21641218]
KB	IC₅₀	> 100 μM Compound: 2, (S)-HPMPC, Cidofovir, CDV	Cytotoxicity against human KB cells after 48 hrs by crystal violet staining based spectrophotometric analysis Cytotoxicity against human KB cells after 48 hrs by crystal violet staining based spectrophotometric analysis	[PMID: 21812420]
ME-180	EC₅₀	64700 nM Compound: Cidofovir	Antiproliferative activity against HPV-transformed human ME180 cells after 7 days by SRB assay Antiproliferative activity against HPV-transformed human ME180 cells after 7 days by SRB assay	[PMID: 19398642]
MOLT-3	EC₅₀	2.1 μg/mL Compound: HPMPC, cidofovir	Antiviral activity against HHV6B strain Z29 in MOLT3 cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against HHV6B strain Z29 in MOLT3 cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17948980]
MRC5	CC₅₀	19 μg/mL Compound: HPMPC	Compound was tested for cytotoxicity by measuring inhibition of MRC-5 cell proliferation. Compound was tested for cytotoxicity by measuring inhibition of MRC-5 cell proliferation.	[PMID: 9934471]
MRC5	IC₅₀	0.04 μg/mL Compound: HPMPC	Compound was tested for cytotoxicity by measuring inhibition of MRC-5 cell proliferation. Compound was tested for cytotoxicity by measuring inhibition of MRC-5 cell proliferation.	[PMID: 9934471]
MRC5	IC₅₀	0.3 μM Compound: CDV	Antiviral activity against Human CMV Towne in MRC5 cells by PRA Antiviral activity against Human CMV Towne in MRC5 cells by PRA	[PMID: 17043128]
MRC5	IC₅₀	0.6 μM Compound: CDV	Antiviral activity against Human CMV T2296 in MRC5 cells by PRA Antiviral activity against Human CMV T2296 in MRC5 cells by PRA	[PMID: 17043128]
MRC5	IC₅₀	1.8 μM Compound: CDV	Antiviral activity against Human CMV T2287 in MRC5 cells by PRA Antiviral activity against Human CMV T2287 in MRC5 cells by PRA	[PMID: 17043128]
MRC5	IC₅₀	10 μM Compound: HPMPC	Inhibitory activity against cytopathic effect of HSV-2(E 194) in MRC-5 cells Inhibitory activity against cytopathic effect of HSV-2(E 194) in MRC-5 cells	[PMID: 8632439]
NHDF	CC₅₀	200 μM Compound: HPMPC	Cytotoxic activity against NHDF cell growth Cytotoxic activity against NHDF cell growth	[PMID: 8632439]
NHDF	IC₅₀	0.5 μM Compound: HPMPC	Inhibitory activity against replication of HCMV in NHDF cells Inhibitory activity against replication of HCMV in NHDF cells	[PMID: 8632439]
Osteoclast-like	IC₅₀	10 μM Compound: cdv	Cytotoxicity against human bone marrow cells assessed as inhibition of colony forming unit of granulocyte/macrophage Cytotoxicity against human bone marrow cells assessed as inhibition of colony forming unit of granulocyte/macrophage	[PMID: 16814545]
SCC-4	EC₅₀	> 100000 nM Compound: Cidofovir	Antiproliferative activity against HPV-non-transformed human SCC4 cells after 7 days by SRB assay Antiproliferative activity against HPV-non-transformed human SCC4 cells after 7 days by SRB assay	[PMID: 19398642]
SCC-9	EC₅₀	> 100000 nM Compound: Cidofovir	Antiproliferative activity against HPV-non-transformed human SCC9 cells after 7 days by SRB assay Antiproliferative activity against HPV-non-transformed human SCC9 cells after 7 days by SRB assay	[PMID: 19398642]
SiHa	EC₅₀	> 100000 nM Compound: Cidofovir	Antiproliferative activity against HPV-transformed human SiHa cells after 7 days by SRB assay Antiproliferative activity against HPV-transformed human SiHa cells after 7 days by SRB assay	[PMID: 19398642]
Vero	CC₅₀	475.3 μM Compound: CDV	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell death Cytotoxicity against African green monkey Vero cells assessed as reduction in cell death	[PMID: 33479623]
Vero	CC₅₀	475.3 μM Compound: Cidofovir	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 4 days by neural red dye-based spectrophotometric method Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 4 days by neural red dye-based spectrophotometric method	[PMID: 30746065]
Vero	CC₅₀	989.25 μM Compound: Cidofovir	Cytotoxicity against African green monkey Vero cells measured after 4 days by colorimetric assay Cytotoxicity against African green monkey Vero cells measured after 4 days by colorimetric assay	[PMID: 36414175]
Vero	CC₅₀	> 720 μM Compound: CFV	Cytotoxicity against african green monkey Vero cells after 2 days Cytotoxicity against african green monkey Vero cells after 2 days	[PMID: 17438061]
Vero	EC₅₀	14.4 μM Compound: CFV	Antiviral activity against Herpes simplex virus 1 F infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs Antiviral activity against Herpes simplex virus 1 F infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs	[PMID: 17438061]
Vero	EC₅₀	21.6 μM Compound: CFV	Antiviral activity against Herpes B virus 32425 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs Antiviral activity against Herpes B virus 32425 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs	[PMID: 17438061]
Vero	EC₅₀	28.9 μM Compound: CFV	Antiviral activity against Herpes B virus 24105 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs Antiviral activity against Herpes B virus 24105 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs	[PMID: 17438061]
Vero	EC₅₀	> 31.5 μg/mL Compound: HPMPC, cidofovir	Antiviral activity against Coxsackie virus B4 in Vero cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Coxsackie virus B4 in Vero cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17948980]
Vero	EC₅₀	> 31.5 μg/mL Compound: HPMPC, cidofovir	Antiviral activity against Parainfluenza 3 in Vero cells reduction of virus-induced cytopathogenicity after 4 days Antiviral activity against Parainfluenza 3 in Vero cells reduction of virus-induced cytopathogenicity after 4 days	[PMID: 17948980]
Vero	EC₅₀	> 31.5 μg/mL Compound: HPMPC, cidofovir	Antiviral activity against Punta Toro virus in Vero cells reduction of virus-induced cytopathogenicity after 4 days Antiviral activity against Punta Toro virus in Vero cells reduction of virus-induced cytopathogenicity after 4 days	[PMID: 17948980]
Vero	EC₅₀	> 31.5 μg/mL Compound: HPMPC, cidofovir	Antiviral activity against Reovirus 1 in Vero cells reduction of virus-induced cytopathogenicity after 4 days Antiviral activity against Reovirus 1 in Vero cells reduction of virus-induced cytopathogenicity after 4 days	[PMID: 17948980]
Vero	EC₅₀	> 31.5 μg/mL Compound: HPMPC, cidofovir	Antiviral activity against Sindbis virus in Vero cells reduction of virus-induced cytopathogenicity after 4 days Antiviral activity against Sindbis virus in Vero cells reduction of virus-induced cytopathogenicity after 4 days	[PMID: 17948980]
Vero	IC₅₀	1.276 μg/mL Compound: cidofovir	Compound concentration to reduce virus cytopathic effect by 50% tested against herpes simplex virus-1(G) using Vero cell line Compound concentration to reduce virus cytopathic effect by 50% tested against herpes simplex virus-1(G) using Vero cell line	[PMID: 15745823]
Vero	IC₅₀	3.937 μg/mL Compound: cidofovir	Compound concentration to reduce virus cytopathic effect by 50% tested against herpes simplex virus-1(KOS) using Vero cell line Compound concentration to reduce virus cytopathic effect by 50% tested against herpes simplex virus-1(KOS) using Vero cell line	[PMID: 15745823]
Vero	IC₅₀	40 μM Compound: Cidofovir	Antiviral activity against Vaccinia virus Copenhagen infected in African green monkey Vero cells assessed as inhibition of viral replication after 4 days by neural red dye-based spectrophotometric method Antiviral activity against Vaccinia virus Copenhagen infected in African green monkey Vero cells assessed as inhibition of viral replication after 4 days by neural red dye-based spectrophotometric method	[PMID: 30746065]
Vero 76	CC₅₀	> 100 μM Compound: CDF	Cytotoxicity against mock-infected African green monkey Vero 76 cells assessed as reduction in proliferation after 48 to 96 hrs by MTT method Cytotoxicity against mock-infected African green monkey Vero 76 cells assessed as reduction in proliferation after 48 to 96 hrs by MTT method	[PMID: 25014745]
Vero 76	EC₅₀	19 μM Compound: CDF	Antiviral activity against Vaccinia virus Lister ATCC VR-1549 infected in Vero 76 cells after 3 days by plaque reduction assays Antiviral activity against Vaccinia virus Lister ATCC VR-1549 infected in Vero 76 cells after 3 days by plaque reduction assays	[PMID: 25014745]
Vero 76	EC₅₀	19 μM Compound: CDF	Antiviral activity against VV Elstree ATCC VR-1549 infected in african green monkey Vero-76 cells after 3 days by plaque reduction assay Antiviral activity against VV Elstree ATCC VR-1549 infected in african green monkey Vero-76 cells after 3 days by plaque reduction assay	[PMID: 26479028]
Vero 76	EC₅₀	> 100 μM Compound: CDF	Antiviral activity against CVB-5 virus Faulkner ATCC VR-185 infected in african green monkey Vero-76 cells after 3 days by plaque reduction assay Antiviral activity against CVB-5 virus Faulkner ATCC VR-185 infected in african green monkey Vero-76 cells after 3 days by plaque reduction assay	[PMID: 26479028]
Vero C1008	IC₅₀	1.8 μM Compound: Cidofovir	Antiviral activity against HSV-1 L2/Rp-ACV/2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect Antiviral activity against HSV-1 L2/Rp-ACV/2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect	[PMID: 28408228]
Vero C1008	IC₅₀	111.9 μM Compound: Cidofovir	Antiviral activity against acyclovir and cidofovir-resistant HSV-1 L2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect Antiviral activity against acyclovir and cidofovir-resistant HSV-1 L2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect	[PMID: 28408228]
Vero C1008	IC₅₀	14 μM Compound: Cidofovir	Antiviral activity against HSV1 L2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect Antiviral activity against HSV1 L2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect	[PMID: 28408228]
Vero C1008	IC₅₀	14 μM Compound: Cidofovir	Antiviral activity against acyclovir-resistant HSV-1 L2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect Antiviral activity against acyclovir-resistant HSV-1 L2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect	[PMID: 28408228]
Vero C1008	IC₅₀	27.9 μM Compound: Cidofovir	Antiviral activity against foscarnet-resistant HSV-1 F+ infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect Antiviral activity against foscarnet-resistant HSV-1 F+ infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect	[PMID: 28408228]
Vero C1008	IC₅₀	7 μM Compound: Cidofovir	Antiviral activity against acyclovir and foscarnet-resistant HSV-1 L2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect Antiviral activity against acyclovir and foscarnet-resistant HSV-1 L2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect	[PMID: 28408228]
WI-38	CC₅₀	10 μg/mL Compound: HPMPC	Compound was tested for antiviral activity against WI-38 cell line using a plaque reduction assay; 10-50 Compound was tested for antiviral activity against WI-38 cell line using a plaque reduction assay; 10-50	[PMID: 9934471]
WI-38	IC₅₀	0.1 μg/mL Compound: HPMPC	Compound was tested for antiviral activity against WI-38 cell line using a plaque reduction assay; 0.1-1 Compound was tested for antiviral activity against WI-38 cell line using a plaque reduction assay; 0.1-1	[PMID: 9934471]

体外研究
(In Vitro)

Cidofovir (5-100 μM, 72 hours) dihydrate has antiviral activity against feline herpesvirus type-1 (FHV-1) with an IC₅₀ of 11 μM, and can reduce Crandell-Reese feline kidney cells counts in a dose dependent manner^[1].
Cidofovir (10-1000 μM, 24-120 hours) dihydrate can reduce cancer cell viability and induces apoptosis^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay^[1]

Cell Line:	Crandell-Reese feline kidney(CRFK) cells
Concentration:	10-100 μM
Incubation Time:	72 hours
Result:	Reduced CRFK cells by 9.1%.

Cell Viability Assay^[3]

Cell Line:	Caco-2, FTC-133, HeLa, Hep-G2, MDA-MB-231, NCI-H1975 and PC-3 cells
Concentration:	10-1000 μM
Incubation Time:	24, 48, 72, 96, 120 hours
Result:	Resulted in a gradual decrease in tumor cell viability with time and concentration increasing and inhibited the number of FTC-133 cell clones by about 55% at 100 μM comparing to the untreated group.

Apoptosis Analysis^[3]

Cell Line:	FTC-133 cells
Concentration:	100 μM
Incubation Time:	96 hours
Result:	Showed a significant increase in the expression of pro-apoptotic proteins, such as cytochrome c, phospho-p53 (S15) and caspase-3 by 130%, 49%, and 46%, respectively while the anti-apoptotic protein Bcl-x decreased significantly by 57% comparing to the untreated cells.

体内研究
(In Vivo)

Cidofovir (subcutaneous injection, 100 mg/kg, 3-6 days interval, 21 days) dihydrate is highly protective against death from cowpox virus (CPV) infection at high doses in female weanling BALB/c mice^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female weanling BALB/c mice infected with cowpox virus (CPV)^[2]
Dosage:	100 mg/kg
Administration:	Subcutaneous injection; 3-6 days interval; 21 days
Result:	Prevented 80-100% of mouse deaths when administered on the first 4-3 days before infection. Protected 35-50% of mice when administered on the fourth day after infection, and 10-20% when administered on the sixth day.

Clinical Trial

分子量

315.22

Formula

C₈H₁₈N₃O₈P

CAS 号

149394-66-1

中文名称

西多福韦二水合物；昔多呋韦二水合物

结构分类

Others

初始来源

内源性代谢物

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

纯度 & 产品资料

产品使用指南 (1538 KB)

参考文献

[1]. David J Maggs, et al. In vitro efficacy of ganciclovir, cidofovir, penciclovir, foscarnet, idoxuridine, and acyclovir against feline herpesvirus type-1. Am J Vet Res. 2004 Apr;65(4):399-403. [Content Brief]

[2]. M Bray, et al. Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge. J Infect Dis. 2000 Jan;181(1):10-9. [Content Brief]

[3]. Simona Catalani, et al. Reduced cell viability and apoptosis induction in human thyroid carcinoma and mesothelioma cells exposed to cidofovir. Toxicol In Vitro. 2017 Jun;41:49-55. [Content Brief]

[4]. Robert O Baker, et al. Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. Antiviral Res. 2003 Jan;57(1-2):13-23. [Content Brief]

Cidofovir dihydrate 相关分类

摩尔计算器
稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量		浓度		体积		分子量 *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)	×	体积 _(start)	=	浓度 _(final)	×	体积 _(final)
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

Cidofovir dihydrate (Synonyms: 西多福韦二水合物; GS 0504 dihydrate; HPMPC dihydrate; (S)-HPMPC dihydrate)

Other Forms of Cidofovir dihydrate:

MCE 顾客使用本产品发表的 10 篇科研文献

Cidofovir dihydrate 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性

纯度 & 产品资料

参考文献

Cidofovir dihydrate 相关分类

摩尔计算器

稀释计算器

The molarity calculator equation

The dilution calculator equation

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Cidofovir dihydrate (Synonyms: 西多福韦二水合物; GS 0504 dihydrate; HPMPC dihydrate; (S)-HPMPC dihydrate)

Other Forms of Cidofovir dihydrate:

Cidofovir dihydrate 相关抗体

MCE 顾客使用本产品发表的 10 篇科研文献

Cidofovir dihydrate 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性

纯度 & 产品资料

参考文献

Cidofovir dihydrate 相关抗体:

Cidofovir dihydrate 相关分类

摩尔计算器

稀释计算器

The molarity calculator equation

The dilution calculator equation

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z